Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2023-09-22
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| x | |
|---|---|
| gag | -212.4848 |
| nef | -196.6982 |
| env | -194.9551 |
| pol | -181.8869 |
| tat | -181.6113 |
| vif | -139.3709 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2630 |
| num_genes_in_profile | 11129 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 6368 |
| num_profile_genes_not_in_sets | 4761 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets: ReactomePathways_2023-09-20.gmt| Gene sets metrics | |
|---|---|
| num_genesets | 2630 |
| num_genesets_excluded | 1322 |
| num_genesets_included | 1308 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Results table
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| APOBEC3G mediated resistance to HIV-1 infection | 10 | 2.65e-05 | -0.767 | 2.63e-04 |
| Mitochondrial translation termination | 88 | 2.26e-27 | -0.668 | 1.11e-24 |
| Mitochondrial translation elongation | 88 | 2.54e-27 | -0.667 | 1.11e-24 |
| Mitochondrial translation initiation | 88 | 3.60e-27 | -0.665 | 1.18e-24 |
| Mitochondrial translation | 94 | 4.94e-28 | -0.655 | 6.46e-25 |
| Metabolism of polyamines | 54 | 3.71e-16 | -0.641 | 5.56e-14 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 2.43e-04 | 0.639 | 1.97e-03 |
| Regulation of ornithine decarboxylase (ODC) | 49 | 2.67e-14 | -0.629 | 3.18e-12 |
| Binding and entry of HIV virion | 11 | 4.55e-04 | -0.610 | 3.46e-03 |
| Folding of actin by CCT/TriC | 10 | 9.41e-04 | -0.604 | 6.38e-03 |
| Vif-mediated degradation of APOBEC3G | 53 | 9.31e-14 | -0.592 | 9.92e-12 |
| Somitogenesis | 46 | 6.33e-12 | -0.586 | 3.19e-10 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 52 | 2.95e-13 | -0.585 | 2.57e-11 |
| Negative regulation of NOTCH4 signaling | 53 | 3.70e-13 | -0.577 | 3.03e-11 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.98e-12 | -0.574 | 3.13e-10 |
| Mitochondrial protein import | 63 | 3.88e-15 | -0.573 | 5.08e-13 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 2.23e-11 | -0.570 | 6.07e-10 |
| Ubiquitin-dependent degradation of Cyclin D | 50 | 5.39e-12 | -0.564 | 2.94e-10 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 49 | 9.87e-12 | -0.562 | 3.57e-10 |
| p53-Independent DNA Damage Response | 49 | 9.87e-12 | -0.562 | 3.57e-10 |
| p53-Independent G1/S DNA damage checkpoint | 49 | 9.87e-12 | -0.562 | 3.57e-10 |
| Defective CFTR causes cystic fibrosis | 57 | 2.19e-13 | -0.562 | 2.05e-11 |
| Gluconeogenesis | 24 | 2.01e-06 | -0.560 | 2.37e-05 |
| SCF(Skp2)-mediated degradation of p27/p21 | 55 | 1.14e-12 | -0.555 | 8.26e-11 |
| Hh mutants are degraded by ERAD | 53 | 2.91e-12 | -0.554 | 1.81e-10 |
| SCF-beta-TrCP mediated degradation of Emi1 | 51 | 7.52e-12 | -0.554 | 3.39e-10 |
| Vpu mediated degradation of CD4 | 51 | 8.62e-12 | -0.553 | 3.57e-10 |
| Regulation of PTEN mRNA translation | 11 | 1.62e-03 | 0.549 | 1.03e-02 |
| tRNA processing in the mitochondrion | 18 | 6.02e-05 | 0.546 | 5.67e-04 |
| Asymmetric localization of PCP proteins | 51 | 1.65e-11 | -0.545 | 4.90e-10 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 4.53e-11 | -0.544 | 1.06e-09 |
| Cholesterol biosynthesis | 25 | 2.96e-06 | -0.540 | 3.43e-05 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 3.11e-03 | 0.540 | 1.73e-02 |
| Degradation of DVL | 53 | 1.16e-11 | -0.539 | 3.80e-10 |
| NRAGE signals death through JNK | 36 | 2.26e-08 | 0.539 | 3.43e-07 |
| Regulation of Apoptosis | 51 | 3.36e-11 | -0.537 | 8.44e-10 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 9.27e-04 | -0.531 | 6.35e-03 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 52 | 3.70e-11 | -0.530 | 9.12e-10 |
| HDMs demethylate histones | 21 | 2.60e-05 | 0.530 | 2.61e-04 |
| Hh mutants abrogate ligand secretion | 54 | 1.72e-11 | -0.529 | 4.93e-10 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 6.39e-13 | -0.528 | 4.92e-11 |
| Complex I biogenesis | 57 | 7.06e-12 | -0.525 | 3.38e-10 |
| Regulation of RUNX3 expression and activity | 55 | 3.13e-11 | -0.518 | 8.03e-10 |
| APC/C:Cdc20 mediated degradation of Securin | 63 | 1.35e-12 | -0.517 | 9.32e-11 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 123 | 6.97e-23 | -0.514 | 1.52e-20 |
| Respiratory electron transport | 103 | 2.16e-19 | -0.514 | 4.03e-17 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 34 | 2.52e-07 | 0.511 | 3.43e-06 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 1.74e-10 | -0.507 | 3.45e-09 |
| 2-LTR circle formation | 12 | 2.58e-03 | -0.503 | 1.47e-02 |
| Orc1 removal from chromatin | 60 | 1.92e-11 | -0.501 | 5.34e-10 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| APOBEC3G mediated resistance to HIV-1 infection | 10 | 2.65e-05 | -0.767000 | 2.63e-04 |
| Mitochondrial translation termination | 88 | 2.26e-27 | -0.668000 | 1.11e-24 |
| Mitochondrial translation elongation | 88 | 2.54e-27 | -0.667000 | 1.11e-24 |
| Mitochondrial translation initiation | 88 | 3.60e-27 | -0.665000 | 1.18e-24 |
| Mitochondrial translation | 94 | 4.94e-28 | -0.655000 | 6.46e-25 |
| Metabolism of polyamines | 54 | 3.71e-16 | -0.641000 | 5.56e-14 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 2.43e-04 | 0.639000 | 1.97e-03 |
| Regulation of ornithine decarboxylase (ODC) | 49 | 2.67e-14 | -0.629000 | 3.18e-12 |
| Binding and entry of HIV virion | 11 | 4.55e-04 | -0.610000 | 3.46e-03 |
| Folding of actin by CCT/TriC | 10 | 9.41e-04 | -0.604000 | 6.38e-03 |
| Vif-mediated degradation of APOBEC3G | 53 | 9.31e-14 | -0.592000 | 9.92e-12 |
| Somitogenesis | 46 | 6.33e-12 | -0.586000 | 3.19e-10 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 52 | 2.95e-13 | -0.585000 | 2.57e-11 |
| Negative regulation of NOTCH4 signaling | 53 | 3.70e-13 | -0.577000 | 3.03e-11 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.98e-12 | -0.574000 | 3.13e-10 |
| Mitochondrial protein import | 63 | 3.88e-15 | -0.573000 | 5.08e-13 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 2.23e-11 | -0.570000 | 6.07e-10 |
| Ubiquitin-dependent degradation of Cyclin D | 50 | 5.39e-12 | -0.564000 | 2.94e-10 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 49 | 9.87e-12 | -0.562000 | 3.57e-10 |
| p53-Independent DNA Damage Response | 49 | 9.87e-12 | -0.562000 | 3.57e-10 |
| p53-Independent G1/S DNA damage checkpoint | 49 | 9.87e-12 | -0.562000 | 3.57e-10 |
| Defective CFTR causes cystic fibrosis | 57 | 2.19e-13 | -0.562000 | 2.05e-11 |
| Gluconeogenesis | 24 | 2.01e-06 | -0.560000 | 2.37e-05 |
| SCF(Skp2)-mediated degradation of p27/p21 | 55 | 1.14e-12 | -0.555000 | 8.26e-11 |
| Hh mutants are degraded by ERAD | 53 | 2.91e-12 | -0.554000 | 1.81e-10 |
| SCF-beta-TrCP mediated degradation of Emi1 | 51 | 7.52e-12 | -0.554000 | 3.39e-10 |
| Vpu mediated degradation of CD4 | 51 | 8.62e-12 | -0.553000 | 3.57e-10 |
| Regulation of PTEN mRNA translation | 11 | 1.62e-03 | 0.549000 | 1.03e-02 |
| tRNA processing in the mitochondrion | 18 | 6.02e-05 | 0.546000 | 5.67e-04 |
| Asymmetric localization of PCP proteins | 51 | 1.65e-11 | -0.545000 | 4.90e-10 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 4.53e-11 | -0.544000 | 1.06e-09 |
| Cholesterol biosynthesis | 25 | 2.96e-06 | -0.540000 | 3.43e-05 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 3.11e-03 | 0.540000 | 1.73e-02 |
| Degradation of DVL | 53 | 1.16e-11 | -0.539000 | 3.80e-10 |
| NRAGE signals death through JNK | 36 | 2.26e-08 | 0.539000 | 3.43e-07 |
| Regulation of Apoptosis | 51 | 3.36e-11 | -0.537000 | 8.44e-10 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 9.27e-04 | -0.531000 | 6.35e-03 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 52 | 3.70e-11 | -0.530000 | 9.12e-10 |
| HDMs demethylate histones | 21 | 2.60e-05 | 0.530000 | 2.61e-04 |
| Hh mutants abrogate ligand secretion | 54 | 1.72e-11 | -0.529000 | 4.93e-10 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 6.39e-13 | -0.528000 | 4.92e-11 |
| Complex I biogenesis | 57 | 7.06e-12 | -0.525000 | 3.38e-10 |
| Regulation of RUNX3 expression and activity | 55 | 3.13e-11 | -0.518000 | 8.03e-10 |
| APC/C:Cdc20 mediated degradation of Securin | 63 | 1.35e-12 | -0.517000 | 9.32e-11 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 123 | 6.97e-23 | -0.514000 | 1.52e-20 |
| Respiratory electron transport | 103 | 2.16e-19 | -0.514000 | 4.03e-17 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 34 | 2.52e-07 | 0.511000 | 3.43e-06 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 1.74e-10 | -0.507000 | 3.45e-09 |
| 2-LTR circle formation | 12 | 2.58e-03 | -0.503000 | 1.47e-02 |
| Orc1 removal from chromatin | 60 | 1.92e-11 | -0.501000 | 5.34e-10 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | 17 | 3.60e-04 | 0.500000 | 2.79e-03 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 10 | 6.23e-03 | -0.500000 | 2.88e-02 |
| Hedgehog ligand biogenesis | 57 | 7.99e-11 | -0.498000 | 1.74e-09 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 60 | 3.07e-11 | -0.496000 | 8.02e-10 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 67 | 2.42e-12 | -0.495000 | 1.58e-10 |
| Regulation of CDH11 Expression and Function | 15 | 9.84e-04 | 0.491000 | 6.63e-03 |
| CDK-mediated phosphorylation and removal of Cdc6 | 64 | 1.10e-11 | -0.491000 | 3.73e-10 |
| NIK–>noncanonical NF-kB signaling | 57 | 1.51e-10 | -0.491000 | 3.05e-09 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 64 | 1.50e-11 | -0.488000 | 4.56e-10 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 64 | 1.50e-11 | -0.488000 | 4.56e-10 |
| Regulation of NPAS4 gene expression | 11 | 5.20e-03 | 0.487000 | 2.60e-02 |
| Myogenesis | 15 | 1.13e-03 | 0.486000 | 7.40e-03 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 66 | 9.98e-12 | -0.485000 | 3.57e-10 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 66 | 9.98e-12 | -0.485000 | 3.57e-10 |
| Formation of ATP by chemiosmotic coupling | 18 | 3.90e-04 | -0.483000 | 2.98e-03 |
| Stabilization of p53 | 54 | 1.03e-09 | -0.480000 | 1.88e-08 |
| Signaling by cytosolic FGFR1 fusion mutants | 17 | 6.13e-04 | 0.480000 | 4.48e-03 |
| Dectin-1 mediated noncanonical NF-kB signaling | 59 | 1.91e-10 | -0.480000 | 3.67e-09 |
| Insulin receptor recycling | 22 | 1.08e-04 | -0.477000 | 9.62e-04 |
| Integration of provirus | 14 | 2.04e-03 | -0.476000 | 1.23e-02 |
| Transferrin endocytosis and recycling | 22 | 1.16e-04 | -0.475000 | 1.02e-03 |
| Degradation of AXIN | 52 | 3.35e-09 | -0.474000 | 5.62e-08 |
| ABC transporter disorders | 63 | 8.99e-11 | -0.473000 | 1.93e-09 |
| Regulation of Expression and Function of Type II Classical Cadherins | 16 | 1.10e-03 | 0.471000 | 7.24e-03 |
| Regulation of Homotypic Cell-Cell Adhesion | 16 | 1.10e-03 | 0.471000 | 7.24e-03 |
| Metabolism of cofactors | 16 | 1.18e-03 | -0.469000 | 7.66e-03 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 25 | 5.13e-05 | -0.468000 | 4.86e-04 |
| Degradation of GLI2 by the proteasome | 56 | 1.59e-09 | -0.466000 | 2.78e-08 |
| GLI3 is processed to GLI3R by the proteasome | 56 | 1.59e-09 | -0.466000 | 2.78e-08 |
| Endosomal/Vacuolar pathway | 10 | 1.07e-02 | 0.466000 | 4.57e-02 |
| Degradation of GLI1 by the proteasome | 56 | 1.86e-09 | -0.465000 | 3.20e-08 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 63 | 1.89e-10 | -0.464000 | 3.67e-09 |
| PCP/CE pathway | 71 | 1.73e-11 | -0.462000 | 4.93e-10 |
| Cristae formation | 31 | 9.05e-06 | -0.461000 | 9.78e-05 |
| NR1H2 and NR1H3-mediated signaling | 39 | 6.89e-07 | 0.460000 | 8.51e-06 |
| Regulation of APC/C activators between G1/S and early anaphase | 69 | 6.13e-11 | -0.456000 | 1.41e-09 |
| Switching of origins to a post-replicative state | 77 | 4.97e-12 | -0.456000 | 2.82e-10 |
| Assembly of the pre-replicative complex | 75 | 1.01e-11 | -0.455000 | 3.57e-10 |
| Translocation of ZAP-70 to Immunological synapse | 10 | 1.31e-02 | 0.453000 | 5.27e-02 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 10 | 1.37e-02 | -0.450000 | 5.44e-02 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 24 | 1.37e-04 | -0.450000 | 1.17e-03 |
| Degradation of cysteine and homocysteine | 10 | 1.44e-02 | -0.447000 | 5.63e-02 |
| Glutathione conjugation | 20 | 5.62e-04 | -0.446000 | 4.17e-03 |
| FGFR1 mutant receptor activation | 20 | 5.64e-04 | 0.445000 | 4.17e-03 |
| Interleukin-6 signaling | 10 | 1.49e-02 | 0.445000 | 5.75e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 169 | 3.69e-23 | -0.443000 | 9.65e-21 |
| ALK mutants bind TKIs | 12 | 8.32e-03 | 0.440000 | 3.65e-02 |
| Metabolism of steroid hormones | 16 | 2.61e-03 | -0.435000 | 1.48e-02 |
| Cohesin Loading onto Chromatin | 10 | 1.82e-02 | 0.431000 | 6.69e-02 |
| Mitotic Telophase/Cytokinesis | 10 | 1.82e-02 | 0.431000 | 6.69e-02 |
| APC/C-mediated degradation of cell cycle proteins | 74 | 1.45e-10 | -0.431000 | 2.97e-09 |
| Regulation of mitotic cell cycle | 74 | 1.45e-10 | -0.431000 | 2.97e-09 |
| Chemokine receptors bind chemokines | 11 | 1.40e-02 | -0.428000 | 5.50e-02 |
| Cellular response to hypoxia | 67 | 1.51e-09 | -0.427000 | 2.70e-08 |
| p53-Dependent G1 DNA Damage Response | 58 | 1.89e-08 | -0.427000 | 2.90e-07 |
| p53-Dependent G1/S DNA damage checkpoint | 58 | 1.89e-08 | -0.427000 | 2.90e-07 |
| DNA Replication Pre-Initiation | 85 | 1.11e-11 | -0.427000 | 3.73e-10 |
| ABC-family proteins mediated transport | 78 | 1.18e-10 | -0.422000 | 2.49e-09 |
| Signaling by BMP | 15 | 4.76e-03 | 0.421000 | 2.44e-02 |
| UCH proteinases | 81 | 7.39e-11 | -0.419000 | 1.64e-09 |
| Activation of NF-kappaB in B cells | 64 | 7.64e-09 | -0.418000 | 1.26e-07 |
| Regulation of RAS by GAPs | 62 | 1.89e-08 | -0.413000 | 2.90e-07 |
| Activation of BAD and translocation to mitochondria | 14 | 7.64e-03 | -0.412000 | 3.41e-02 |
| Transcriptional Regulation by NPAS4 | 24 | 4.86e-04 | 0.412000 | 3.65e-03 |
| Synthesis of PIPs at the early endosome membrane | 15 | 6.00e-03 | 0.410000 | 2.82e-02 |
| G1/S DNA Damage Checkpoints | 59 | 5.67e-08 | -0.409000 | 8.06e-07 |
| Synthesis of DNA | 97 | 3.80e-12 | -0.408000 | 2.26e-10 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.11e-02 | -0.407000 | 4.62e-02 |
| Regulation of RUNX2 expression and activity | 63 | 2.80e-08 | -0.405000 | 4.21e-07 |
| G alpha (12/13) signalling events | 47 | 1.68e-06 | 0.404000 | 2.02e-05 |
| Synthesis of PIPs at the late endosome membrane | 10 | 2.79e-02 | 0.402000 | 9.42e-02 |
| Formation of paraxial mesoderm | 55 | 3.04e-07 | -0.399000 | 4.02e-06 |
| Growth hormone receptor signaling | 15 | 7.53e-03 | 0.399000 | 3.39e-02 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 29 | 2.13e-04 | 0.397000 | 1.74e-03 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 61 | 1.07e-07 | -0.394000 | 1.48e-06 |
| Phosphorylation of CD3 and TCR zeta chains | 14 | 1.09e-02 | 0.393000 | 4.62e-02 |
| DNA Replication | 102 | 8.09e-12 | -0.392000 | 3.53e-10 |
| Interleukin-6 family signaling | 11 | 2.44e-02 | 0.392000 | 8.55e-02 |
| Synthesis of PIPs at the plasma membrane | 45 | 6.67e-06 | 0.388000 | 7.40e-05 |
| Early Phase of HIV Life Cycle | 21 | 2.21e-03 | -0.386000 | 1.30e-02 |
| Interconversion of nucleotide di- and triphosphates | 24 | 1.08e-03 | -0.386000 | 7.21e-03 |
| Generation of second messenger molecules | 18 | 4.64e-03 | 0.386000 | 2.39e-02 |
| FCERI mediated NF-kB activation | 74 | 1.16e-08 | -0.384000 | 1.85e-07 |
| Interleukin-2 family signaling | 30 | 2.84e-04 | 0.383000 | 2.25e-03 |
| Pre-NOTCH Transcription and Translation | 30 | 2.91e-04 | 0.382000 | 2.29e-03 |
| Regulation of PTEN stability and activity | 65 | 1.11e-07 | -0.381000 | 1.53e-06 |
| Formation of tubulin folding intermediates by CCT/TriC | 18 | 5.27e-03 | -0.380000 | 2.63e-02 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 1.10e-02 | -0.379000 | 4.62e-02 |
| Interleukin receptor SHC signaling | 18 | 5.62e-03 | 0.377000 | 2.69e-02 |
| Nephrin family interactions | 15 | 1.18e-02 | 0.376000 | 4.82e-02 |
| FOXO-mediated transcription of cell death genes | 14 | 1.50e-02 | 0.376000 | 5.77e-02 |
| Nucleotide biosynthesis | 11 | 3.17e-02 | -0.374000 | 1.04e-01 |
| FCERI mediated Ca+2 mobilization | 24 | 1.55e-03 | 0.373000 | 9.96e-03 |
| Regulation of beta-cell development | 16 | 1.01e-02 | 0.371000 | 4.35e-02 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 13 | 2.04e-02 | -0.371000 | 7.42e-02 |
| Cyclin E associated events during G1/S transition | 74 | 3.42e-08 | -0.371000 | 5.03e-07 |
| RORA activates gene expression | 18 | 6.63e-03 | 0.370000 | 3.05e-02 |
| Cyclin A:Cdk2-associated events at S phase entry | 76 | 2.86e-08 | -0.369000 | 4.24e-07 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 16 | 1.08e-02 | 0.368000 | 4.58e-02 |
| FGFR2 mutant receptor activation | 16 | 1.11e-02 | -0.367000 | 4.62e-02 |
| Signaling by FGFR2 IIIa TM | 16 | 1.11e-02 | -0.367000 | 4.62e-02 |
| Heme signaling | 38 | 1.02e-04 | 0.364000 | 9.13e-04 |
| rRNA processing in the mitochondrion | 21 | 3.90e-03 | 0.364000 | 2.09e-02 |
| Signaling by Erythropoietin | 23 | 2.55e-03 | 0.364000 | 1.46e-02 |
| Sulfur amino acid metabolism | 19 | 6.20e-03 | -0.363000 | 2.87e-02 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 84 | 9.74e-09 | -0.362000 | 1.59e-07 |
| TNFR2 non-canonical NF-kB pathway | 77 | 4.30e-08 | -0.361000 | 6.25e-07 |
| Downstream signaling events of B Cell Receptor (BCR) | 77 | 4.73e-08 | -0.360000 | 6.80e-07 |
| Signaling by FGFR1 in disease | 26 | 1.51e-03 | 0.360000 | 9.74e-03 |
| NOTCH3 Intracellular Domain Regulates Transcription | 16 | 1.29e-02 | 0.359000 | 5.20e-02 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 32 | 4.59e-04 | -0.358000 | 3.47e-03 |
| Signaling by NOTCH4 | 75 | 9.01e-08 | -0.357000 | 1.27e-06 |
| Hedgehog ‘on’ state | 65 | 6.47e-07 | -0.357000 | 8.06e-06 |
| RHOB GTPase cycle | 48 | 1.90e-05 | 0.357000 | 1.96e-04 |
| Citric acid cycle (TCA cycle) | 22 | 3.92e-03 | -0.355000 | 2.09e-02 |
| Synthesis of IP3 and IP4 in the cytosol | 14 | 2.19e-02 | 0.354000 | 7.84e-02 |
| Methylation | 10 | 5.35e-02 | -0.353000 | 1.53e-01 |
| Notch-HLH transcription pathway | 26 | 1.89e-03 | 0.352000 | 1.14e-02 |
| Cell-extracellular matrix interactions | 13 | 2.84e-02 | -0.351000 | 9.57e-02 |
| G2/M Checkpoints | 107 | 4.81e-10 | -0.349000 | 8.98e-09 |
| NPAS4 regulates expression of target genes | 13 | 3.03e-02 | 0.347000 | 1.00e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 11 | 4.64e-02 | 0.347000 | 1.41e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 22 | 4.99e-03 | 0.346000 | 2.53e-02 |
| Cell death signalling via NRAGE, NRIF and NADE | 53 | 1.40e-05 | 0.345000 | 1.49e-04 |
| PI3K Cascade | 18 | 1.14e-02 | 0.345000 | 4.71e-02 |
| RAC1 GTPase cycle | 135 | 7.24e-12 | 0.342000 | 3.38e-10 |
| CDC42 GTPase cycle | 112 | 5.84e-10 | 0.339000 | 1.08e-08 |
| KSRP (KHSRP) binds and destabilizes mRNA | 16 | 1.88e-02 | -0.339000 | 6.85e-02 |
| mRNA Splicing - Minor Pathway | 50 | 3.54e-05 | -0.338000 | 3.48e-04 |
| Apoptotic cleavage of cellular proteins | 27 | 2.36e-03 | 0.338000 | 1.37e-02 |
| Regulation of IFNA/IFNB signaling | 12 | 4.27e-02 | 0.338000 | 1.31e-01 |
| Diseases associated with N-glycosylation of proteins | 20 | 8.99e-03 | -0.338000 | 3.91e-02 |
| Role of phospholipids in phagocytosis | 18 | 1.39e-02 | 0.335000 | 5.50e-02 |
| Budding and maturation of HIV virion | 34 | 8.10e-04 | -0.332000 | 5.63e-03 |
| Purine catabolism | 13 | 3.96e-02 | -0.330000 | 1.23e-01 |
| Amino acids regulate mTORC1 | 45 | 1.34e-04 | -0.329000 | 1.15e-03 |
| Interferon alpha/beta signaling | 56 | 2.22e-05 | 0.328000 | 2.27e-04 |
| Other semaphorin interactions | 12 | 4.93e-02 | 0.328000 | 1.46e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 14 | 3.40e-02 | 0.327000 | 1.10e-01 |
| G1/S Transition | 104 | 9.98e-09 | -0.326000 | 1.61e-07 |
| Pausing and recovery of Tat-mediated HIV elongation | 31 | 1.79e-03 | -0.324000 | 1.10e-02 |
| Tat-mediated HIV elongation arrest and recovery | 31 | 1.79e-03 | -0.324000 | 1.10e-02 |
| ER-Phagosome pathway | 83 | 3.60e-07 | -0.324000 | 4.66e-06 |
| Signaling by CSF1 (M-CSF) in myeloid cells | 28 | 3.17e-03 | 0.322000 | 1.76e-02 |
| Chondroitin sulfate biosynthesis | 10 | 7.89e-02 | 0.321000 | 2.01e-01 |
| Interleukin-15 signaling | 11 | 6.54e-02 | 0.321000 | 1.75e-01 |
| Glyoxylate metabolism and glycine degradation | 21 | 1.12e-02 | -0.320000 | 4.62e-02 |
| Inositol phosphate metabolism | 29 | 2.91e-03 | 0.320000 | 1.63e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 4.09e-03 | -0.319000 | 2.14e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 4.09e-03 | -0.319000 | 2.14e-02 |
| Protein localization | 149 | 2.98e-11 | -0.316000 | 7.97e-10 |
| Regulation of RUNX1 Expression and Activity | 17 | 2.44e-02 | 0.315000 | 8.55e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 9.28e-03 | -0.314000 | 4.02e-02 |
| PI Metabolism | 68 | 8.02e-06 | 0.313000 | 8.74e-05 |
| Degradation of beta-catenin by the destruction complex | 76 | 2.40e-06 | -0.313000 | 2.80e-05 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 16 | 3.02e-02 | -0.313000 | 1.00e-01 |
| mRNA Capping | 29 | 3.57e-03 | -0.313000 | 1.95e-02 |
| NGF-stimulated transcription | 26 | 5.82e-03 | 0.313000 | 2.76e-02 |
| GPVI-mediated activation cascade | 28 | 4.51e-03 | 0.310000 | 2.33e-02 |
| tRNA Aminoacylation | 21 | 1.41e-02 | -0.309000 | 5.55e-02 |
| PRC2 methylates histones and DNA | 13 | 5.35e-02 | 0.309000 | 1.53e-01 |
| RNA Polymerase III Chain Elongation | 17 | 2.74e-02 | -0.309000 | 9.35e-02 |
| Regulation of TP53 Activity through Association with Co-factors | 10 | 9.23e-02 | 0.307000 | 2.21e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 10 | 9.24e-02 | 0.307000 | 2.21e-01 |
| Host Interactions of HIV factors | 129 | 2.84e-09 | -0.304000 | 4.83e-08 |
| Metabolism of folate and pterines | 15 | 4.24e-02 | -0.303000 | 1.31e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 14 | 5.03e-02 | 0.302000 | 1.47e-01 |
| Interleukin-20 family signaling | 14 | 5.09e-02 | 0.301000 | 1.48e-01 |
| Interleukin-12 signaling | 37 | 1.58e-03 | -0.300000 | 1.01e-02 |
| PIWI-interacting RNA (piRNA) biogenesis | 17 | 3.26e-02 | -0.299000 | 1.07e-01 |
| FOXO-mediated transcription of cell cycle genes | 11 | 8.58e-02 | 0.299000 | 2.12e-01 |
| Assembly Of The HIV Virion | 22 | 1.54e-02 | -0.299000 | 5.84e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 43 | 7.21e-04 | -0.298000 | 5.10e-03 |
| HIV Transcription Elongation | 43 | 7.21e-04 | -0.298000 | 5.10e-03 |
| Tat-mediated elongation of the HIV-1 transcript | 43 | 7.21e-04 | -0.298000 | 5.10e-03 |
| Class I peroxisomal membrane protein import | 18 | 2.88e-02 | -0.298000 | 9.63e-02 |
| Inhibition of DNA recombination at telomere | 21 | 1.83e-02 | -0.298000 | 6.69e-02 |
| rRNA modification in the nucleus and cytosol | 55 | 1.37e-04 | -0.298000 | 1.17e-03 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 27 | 7.65e-03 | 0.297000 | 3.41e-02 |
| ROS and RNS production in phagocytes | 25 | 1.10e-02 | -0.294000 | 4.62e-02 |
| Transcriptional regulation by RUNX2 | 90 | 1.55e-06 | -0.293000 | 1.87e-05 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 3.69e-02 | -0.292000 | 1.17e-01 |
| Pre-NOTCH Expression and Processing | 45 | 7.60e-04 | 0.290000 | 5.32e-03 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 38 | 2.06e-03 | 0.289000 | 1.23e-02 |
| Formation of the Early Elongation Complex | 33 | 4.10e-03 | -0.289000 | 2.14e-02 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 4.10e-03 | -0.289000 | 2.14e-02 |
| RAF-independent MAPK1/3 activation | 18 | 3.42e-02 | 0.288000 | 1.10e-01 |
| Triglyceride catabolism | 13 | 7.39e-02 | -0.286000 | 1.93e-01 |
| Peroxisomal lipid metabolism | 24 | 1.53e-02 | -0.286000 | 5.84e-02 |
| DAP12 signaling | 24 | 1.54e-02 | 0.286000 | 5.84e-02 |
| MAPK6/MAPK4 signaling | 77 | 1.52e-05 | -0.286000 | 1.60e-04 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 27 | 1.03e-02 | -0.285000 | 4.41e-02 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 10 | 1.18e-01 | -0.285000 | 2.68e-01 |
| Circadian Clock | 59 | 1.54e-04 | 0.285000 | 1.30e-03 |
| Signaling by FLT3 fusion proteins | 18 | 3.75e-02 | 0.283000 | 1.18e-01 |
| Pyroptosis | 24 | 1.72e-02 | -0.281000 | 6.38e-02 |
| Regulation of IFNG signaling | 13 | 8.01e-02 | 0.280000 | 2.04e-01 |
| PKMTs methylate histone lysines | 37 | 3.45e-03 | 0.278000 | 1.90e-02 |
| PD-1 signaling | 14 | 7.25e-02 | 0.277000 | 1.91e-01 |
| RHO GTPases activate PAKs | 18 | 4.19e-02 | -0.277000 | 1.30e-01 |
| IRS-related events triggered by IGF1R | 23 | 2.18e-02 | 0.276000 | 7.84e-02 |
| Prolonged ERK activation events | 12 | 9.86e-02 | 0.275000 | 2.32e-01 |
| Nuclear events mediated by NFE2L2 | 89 | 7.36e-06 | -0.275000 | 8.09e-05 |
| HIV elongation arrest and recovery | 32 | 7.08e-03 | -0.275000 | 3.20e-02 |
| Pausing and recovery of HIV elongation | 32 | 7.08e-03 | -0.275000 | 3.20e-02 |
| Receptor Mediated Mitophagy | 11 | 1.17e-01 | -0.273000 | 2.67e-01 |
| Signaling by PDGFR in disease | 19 | 3.98e-02 | 0.273000 | 1.24e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 26 | 1.66e-02 | -0.272000 | 6.20e-02 |
| Regulation of signaling by CBL | 21 | 3.19e-02 | 0.271000 | 1.05e-01 |
| Amyloid fiber formation | 33 | 7.32e-03 | 0.270000 | 3.30e-02 |
| FCGR3A-mediated IL10 synthesis | 27 | 1.54e-02 | 0.270000 | 5.84e-02 |
| Hedgehog ‘off’ state | 90 | 1.09e-05 | -0.269000 | 1.16e-04 |
| RHOBTB1 GTPase cycle | 23 | 2.64e-02 | 0.268000 | 9.13e-02 |
| PKA-mediated phosphorylation of CREB | 14 | 8.37e-02 | 0.267000 | 2.09e-01 |
| Removal of the Flap Intermediate from the C-strand | 16 | 6.49e-02 | -0.267000 | 1.74e-01 |
| Ca2+ pathway | 37 | 5.11e-03 | 0.266000 | 2.57e-02 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 27 | 1.68e-02 | -0.266000 | 6.28e-02 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 17 | 5.79e-02 | 0.266000 | 1.60e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 47 | 1.81e-03 | 0.263000 | 1.11e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.54e-03 | -0.263000 | 1.46e-02 |
| Apoptotic execution phase | 34 | 8.23e-03 | 0.262000 | 3.62e-02 |
| Heme biosynthesis | 12 | 1.18e-01 | -0.261000 | 2.67e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 6.38e-02 | -0.260000 | 1.72e-01 |
| Retinoid metabolism and transport | 19 | 5.03e-02 | 0.260000 | 1.47e-01 |
| Telomere Maintenance | 55 | 9.01e-04 | -0.259000 | 6.24e-03 |
| WNT5A-dependent internalization of FZD4 | 12 | 1.21e-01 | -0.259000 | 2.72e-01 |
| RHOA GTPase cycle | 106 | 4.65e-06 | 0.258000 | 5.33e-05 |
| IGF1R signaling cascade | 24 | 2.90e-02 | 0.258000 | 9.63e-02 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 24 | 2.90e-02 | 0.258000 | 9.63e-02 |
| HIV Infection | 223 | 4.21e-11 | -0.257000 | 1.00e-09 |
| Mitochondrial RNA degradation | 23 | 3.28e-02 | 0.257000 | 1.07e-01 |
| HDACs deacetylate histones | 32 | 1.20e-02 | 0.257000 | 4.88e-02 |
| Adherens junctions interactions | 25 | 2.63e-02 | 0.257000 | 9.13e-02 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | 37 | 6.91e-03 | 0.257000 | 3.16e-02 |
| S Phase | 132 | 4.11e-07 | -0.256000 | 5.27e-06 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | 16 | 7.71e-02 | 0.255000 | 1.98e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 50 | 1.88e-03 | -0.254000 | 1.14e-02 |
| mTORC1-mediated signalling | 24 | 3.15e-02 | -0.254000 | 1.04e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 18 | 6.25e-02 | -0.254000 | 1.70e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 1.46e-01 | 0.253000 | 3.07e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 10 | 1.66e-01 | 0.253000 | 3.36e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 13 | 1.16e-01 | -0.252000 | 2.66e-01 |
| Cell-cell junction organization | 33 | 1.24e-02 | 0.252000 | 5.04e-02 |
| Formation of TC-NER Pre-Incision Complex | 53 | 1.69e-03 | -0.250000 | 1.05e-02 |
| Maternal to zygotic transition (MZT) | 50 | 2.32e-03 | 0.249000 | 1.36e-02 |
| DNA Damage Recognition in GG-NER | 37 | 8.85e-03 | -0.249000 | 3.86e-02 |
| DAP12 interactions | 30 | 1.85e-02 | 0.249000 | 6.77e-02 |
| Removal of the Flap Intermediate | 13 | 1.21e-01 | -0.248000 | 2.72e-01 |
| RNA Polymerase III Transcription Termination | 20 | 5.52e-02 | -0.248000 | 1.55e-01 |
| HIV Transcription Initiation | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| RNA Polymerase II HIV Promoter Escape | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| RNA Polymerase II Promoter Escape | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| RNA Polymerase II Transcription Initiation | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 42 | 5.52e-03 | -0.248000 | 2.66e-02 |
| Downstream TCR signaling | 84 | 9.24e-05 | -0.247000 | 8.42e-04 |
| RAS processing | 20 | 5.59e-02 | -0.247000 | 1.56e-01 |
| Transcription of the HIV genome | 65 | 5.90e-04 | -0.247000 | 4.34e-03 |
| CLEC7A (Dectin-1) signaling | 94 | 3.87e-05 | -0.246000 | 3.78e-04 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 16 | 8.91e-02 | -0.246000 | 2.16e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 16 | 8.91e-02 | -0.246000 | 2.16e-01 |
| HS-GAG biosynthesis | 16 | 9.01e-02 | 0.245000 | 2.17e-01 |
| IRS-mediated signalling | 22 | 4.70e-02 | 0.245000 | 1.42e-01 |
| Mitotic G1 phase and G1/S transition | 118 | 4.68e-06 | -0.245000 | 5.33e-05 |
| RHOJ GTPase cycle | 47 | 3.83e-03 | 0.244000 | 2.06e-02 |
| Interferon gamma signaling | 73 | 3.47e-04 | 0.243000 | 2.70e-03 |
| Translation | 266 | 1.35e-11 | -0.242000 | 4.31e-10 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 30 | 2.21e-02 | -0.242000 | 7.89e-02 |
| RND3 GTPase cycle | 28 | 2.72e-02 | 0.241000 | 9.32e-02 |
| RUNX3 regulates NOTCH signaling | 13 | 1.34e-01 | 0.240000 | 2.90e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 13 | 1.34e-01 | -0.240000 | 2.90e-01 |
| Uptake and function of anthrax toxins | 10 | 1.89e-01 | 0.240000 | 3.65e-01 |
| RHO GTPase cycle | 332 | 9.86e-14 | 0.239000 | 9.92e-12 |
| Nuclear Events (kinase and transcription factor activation) | 46 | 5.10e-03 | 0.239000 | 2.57e-02 |
| Interleukin-7 signaling | 12 | 1.52e-01 | 0.239000 | 3.16e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 26 | 3.53e-02 | -0.239000 | 1.13e-01 |
| Telomere Extension By Telomerase | 17 | 8.87e-02 | -0.239000 | 2.15e-01 |
| Phase II - Conjugation of compounds | 46 | 5.46e-03 | -0.237000 | 2.66e-02 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 1.12e-01 | -0.237000 | 2.61e-01 |
| RNA Polymerase III Transcription Initiation | 34 | 1.71e-02 | -0.237000 | 6.34e-02 |
| Gastrulation | 68 | 7.59e-04 | -0.236000 | 5.32e-03 |
| Polymerase switching on the C-strand of the telomere | 22 | 5.55e-02 | -0.236000 | 1.55e-01 |
| Signaling by ALK fusions and activated point mutants | 50 | 3.94e-03 | 0.236000 | 2.09e-02 |
| Signaling by ALK in cancer | 50 | 3.94e-03 | 0.236000 | 2.09e-02 |
| Metabolism of nucleotides | 77 | 3.73e-04 | -0.235000 | 2.87e-03 |
| RHOBTB GTPase Cycle | 35 | 1.65e-02 | 0.234000 | 6.20e-02 |
| Processing and activation of SUMO | 10 | 2.00e-01 | -0.234000 | 3.80e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 65 | 1.12e-03 | -0.234000 | 7.39e-03 |
| Regulation of MECP2 expression and activity | 27 | 3.59e-02 | 0.233000 | 1.14e-01 |
| RNA Polymerase I Transcription Termination | 24 | 4.83e-02 | -0.233000 | 1.44e-01 |
| p75 NTR receptor-mediated signalling | 73 | 6.32e-04 | 0.232000 | 4.59e-03 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 2.06e-01 | -0.231000 | 3.85e-01 |
| FGFR2 alternative splicing | 24 | 5.01e-02 | -0.231000 | 1.47e-01 |
| RNA Polymerase I Promoter Escape | 26 | 4.28e-02 | -0.230000 | 1.31e-01 |
| Separation of Sister Chromatids | 147 | 1.74e-06 | -0.229000 | 2.06e-05 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 25 | 4.77e-02 | 0.229000 | 1.43e-01 |
| Collagen biosynthesis and modifying enzymes | 19 | 8.44e-02 | -0.229000 | 2.10e-01 |
| Transcriptional regulation of granulopoiesis | 22 | 6.35e-02 | 0.229000 | 1.72e-01 |
| tRNA modification in the nucleus and cytosol | 38 | 1.49e-02 | -0.228000 | 5.75e-02 |
| Metabolic disorders of biological oxidation enzymes | 16 | 1.14e-01 | -0.228000 | 2.62e-01 |
| Rap1 signalling | 12 | 1.78e-01 | -0.225000 | 3.51e-01 |
| RHOC GTPase cycle | 56 | 3.70e-03 | 0.225000 | 2.01e-02 |
| Extension of Telomeres | 40 | 1.42e-02 | -0.224000 | 5.58e-02 |
| Interleukin-1 signaling | 105 | 7.53e-05 | -0.224000 | 7.04e-04 |
| Attachment and Entry 9694614 | 11 | 1.99e-01 | 0.224000 | 3.80e-01 |
| Phosphorylation of the APC/C | 16 | 1.23e-01 | -0.223000 | 2.75e-01 |
| FLT3 signaling in disease | 25 | 5.42e-02 | 0.223000 | 1.53e-01 |
| Processive synthesis on the C-strand of the telomere | 18 | 1.05e-01 | -0.221000 | 2.46e-01 |
| Josephin domain DUBs | 10 | 2.27e-01 | -0.220000 | 4.10e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 1.28e-01 | 0.220000 | 2.83e-01 |
| Deadenylation of mRNA | 22 | 7.48e-02 | 0.220000 | 1.95e-01 |
| Processive synthesis on the lagging strand | 14 | 1.56e-01 | -0.219000 | 3.21e-01 |
| Disorders of transmembrane transporters | 119 | 4.28e-05 | -0.218000 | 4.11e-04 |
| Pyruvate metabolism | 26 | 5.49e-02 | -0.218000 | 1.55e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 1.75e-01 | 0.217000 | 3.47e-01 |
| Beta-catenin independent WNT signaling | 107 | 1.12e-04 | -0.217000 | 9.91e-04 |
| Chaperone Mediated Autophagy | 18 | 1.12e-01 | 0.216000 | 2.61e-01 |
| RHO GTPases activate PKNs | 26 | 5.62e-02 | -0.216000 | 1.57e-01 |
| Paracetamol ADME | 11 | 2.14e-01 | -0.216000 | 3.95e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 2.37e-01 | -0.216000 | 4.22e-01 |
| Insulin receptor signalling cascade | 27 | 5.25e-02 | 0.216000 | 1.51e-01 |
| SUMOylation of immune response proteins | 11 | 2.16e-01 | -0.216000 | 3.96e-01 |
| Detoxification of Reactive Oxygen Species | 28 | 4.87e-02 | -0.215000 | 1.45e-01 |
| Cleavage of the damaged pyrimidine | 14 | 1.63e-01 | -0.215000 | 3.32e-01 |
| Depyrimidination | 14 | 1.63e-01 | -0.215000 | 3.32e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 14 | 1.63e-01 | -0.215000 | 3.32e-01 |
| Mitotic Anaphase | 187 | 4.54e-07 | -0.215000 | 5.71e-06 |
| Mitotic Metaphase and Anaphase | 187 | 4.54e-07 | -0.215000 | 5.71e-06 |
| Antigen processing-Cross presentation | 97 | 2.69e-04 | -0.214000 | 2.16e-03 |
| Cell Cycle Checkpoints | 196 | 2.61e-07 | -0.214000 | 3.51e-06 |
| Amino acid transport across the plasma membrane | 18 | 1.17e-01 | 0.214000 | 2.66e-01 |
| Negative regulation of MET activity | 16 | 1.40e-01 | 0.213000 | 2.99e-01 |
| Nucleotide Excision Repair | 105 | 1.66e-04 | -0.213000 | 1.37e-03 |
| KEAP1-NFE2L2 pathway | 114 | 9.71e-05 | -0.212000 | 8.76e-04 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 17 | 1.31e-01 | -0.211000 | 2.87e-01 |
| RND1 GTPase cycle | 28 | 5.30e-02 | 0.211000 | 1.52e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 18 | 1.21e-01 | 0.211000 | 2.72e-01 |
| p38MAPK events | 11 | 2.26e-01 | -0.211000 | 4.09e-01 |
| Acyl chain remodelling of PE | 10 | 2.48e-01 | 0.211000 | 4.38e-01 |
| Activation of G protein gated Potassium channels | 11 | 2.27e-01 | -0.210000 | 4.10e-01 |
| G protein gated Potassium channels | 11 | 2.27e-01 | -0.210000 | 4.10e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 11 | 2.27e-01 | -0.210000 | 4.10e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 18 | 1.23e-01 | -0.210000 | 2.75e-01 |
| C-type lectin receptors (CLRs) | 113 | 1.19e-04 | -0.210000 | 1.03e-03 |
| RNA Polymerase III Abortive And Retractive Initiation | 37 | 2.77e-02 | -0.209000 | 9.39e-02 |
| RNA Polymerase III Transcription | 37 | 2.77e-02 | -0.209000 | 9.39e-02 |
| Chondroitin sulfate/dermatan sulfate metabolism | 29 | 5.14e-02 | 0.209000 | 1.49e-01 |
| Transcriptional regulation by RUNX3 | 88 | 7.14e-04 | -0.209000 | 5.10e-03 |
| Signaling by the B Cell Receptor (BCR) | 101 | 2.96e-04 | -0.209000 | 2.32e-03 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 10 | 2.53e-01 | 0.209000 | 4.44e-01 |
| RET signaling | 23 | 8.40e-02 | 0.208000 | 2.09e-01 |
| Iron uptake and transport | 45 | 1.59e-02 | -0.208000 | 6.01e-02 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 75 | 1.92e-03 | -0.208000 | 1.16e-02 |
| Post-chaperonin tubulin folding pathway | 14 | 1.79e-01 | -0.207000 | 3.53e-01 |
| Activation of AMPK downstream of NMDARs | 16 | 1.52e-01 | -0.207000 | 3.16e-01 |
| Azathioprine ADME | 17 | 1.41e-01 | -0.206000 | 3.00e-01 |
| RHOU GTPase cycle | 35 | 3.51e-02 | 0.206000 | 1.12e-01 |
| Interleukin-12 family signaling | 42 | 2.11e-02 | -0.206000 | 7.59e-02 |
| Post-translational modification: synthesis of GPI-anchored proteins | 39 | 2.66e-02 | -0.205000 | 9.19e-02 |
| Cellular response to chemical stress | 189 | 1.37e-06 | -0.204000 | 1.67e-05 |
| RHO GTPases activate IQGAPs | 22 | 9.81e-02 | -0.204000 | 2.32e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 21 | 1.06e-01 | -0.204000 | 2.49e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 79 | 1.78e-03 | -0.204000 | 1.10e-02 |
| Telomere C-strand (Lagging Strand) Synthesis | 29 | 5.83e-02 | -0.203000 | 1.61e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 42 | 2.29e-02 | 0.203000 | 8.12e-02 |
| Synthesis of PIPs at the Golgi membrane | 14 | 1.89e-01 | 0.203000 | 3.65e-01 |
| Repression of WNT target genes | 10 | 2.67e-01 | 0.203000 | 4.57e-01 |
| G-protein mediated events | 36 | 3.55e-02 | 0.203000 | 1.13e-01 |
| Glucagon-type ligand receptors | 11 | 2.46e-01 | -0.202000 | 4.35e-01 |
| Prostacyclin signalling through prostacyclin receptor | 11 | 2.46e-01 | -0.202000 | 4.35e-01 |
| Synthesis of substrates in N-glycan biosythesis | 50 | 1.35e-02 | -0.202000 | 5.39e-02 |
| Mitophagy | 28 | 6.45e-02 | -0.202000 | 1.73e-01 |
| Dual incision in TC-NER | 62 | 6.06e-03 | -0.202000 | 2.83e-02 |
| Protein folding | 70 | 3.61e-03 | -0.201000 | 1.97e-02 |
| Smooth Muscle Contraction | 26 | 7.57e-02 | -0.201000 | 1.96e-01 |
| Inactivation of CSF3 (G-CSF) signaling | 24 | 8.79e-02 | 0.201000 | 2.15e-01 |
| TP53 Regulates Metabolic Genes | 82 | 1.68e-03 | -0.201000 | 1.05e-02 |
| Signaling by FGFR2 in disease | 25 | 8.23e-02 | -0.201000 | 2.08e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 61 | 7.05e-03 | -0.200000 | 3.20e-02 |
| Chaperonin-mediated protein folding | 65 | 5.44e-03 | -0.200000 | 2.66e-02 |
| Telomere C-strand synthesis initiation | 13 | 2.14e-01 | -0.199000 | 3.95e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 10 | 2.77e-01 | -0.198000 | 4.71e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 20 | 1.25e-01 | -0.198000 | 2.78e-01 |
| COPI-mediated anterograde transport | 81 | 2.10e-03 | -0.198000 | 1.25e-02 |
| Mismatch Repair | 14 | 2.00e-01 | -0.198000 | 3.80e-01 |
| Late Phase of HIV Life Cycle | 135 | 7.63e-05 | -0.198000 | 7.06e-04 |
| Signaling by NOTCH2 | 24 | 9.46e-02 | 0.197000 | 2.25e-01 |
| Antimicrobial peptides | 15 | 1.86e-01 | 0.197000 | 3.63e-01 |
| Protein hydroxylation | 15 | 1.87e-01 | -0.197000 | 3.63e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 22 | 1.11e-01 | -0.196000 | 2.59e-01 |
| LDL clearance | 15 | 1.88e-01 | -0.196000 | 3.65e-01 |
| IRE1alpha activates chaperones | 43 | 2.68e-02 | -0.195000 | 9.24e-02 |
| Formation of the beta-catenin:TCF transactivating complex | 25 | 9.19e-02 | 0.195000 | 2.21e-01 |
| Activation of the pre-replicative complex | 19 | 1.42e-01 | -0.195000 | 3.00e-01 |
| Signaling by NODAL | 12 | 2.44e-01 | 0.194000 | 4.33e-01 |
| Frs2-mediated activation | 10 | 2.88e-01 | 0.194000 | 4.81e-01 |
| Chromatin modifying enzymes | 189 | 5.09e-06 | 0.193000 | 5.69e-05 |
| Chromatin organization | 189 | 5.09e-06 | 0.193000 | 5.69e-05 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 1.96e-01 | 0.193000 | 3.77e-01 |
| PLC beta mediated events | 34 | 5.19e-02 | 0.193000 | 1.50e-01 |
| TRAF6 mediated IRF7 activation | 15 | 1.98e-01 | 0.192000 | 3.79e-01 |
| Mitochondrial calcium ion transport | 20 | 1.38e-01 | -0.192000 | 2.97e-01 |
| Laminin interactions | 10 | 2.94e-01 | -0.192000 | 4.88e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 5.40e-02 | 0.191000 | 1.53e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 33 | 5.76e-02 | -0.191000 | 1.60e-01 |
| BBSome-mediated cargo-targeting to cilium | 18 | 1.61e-01 | -0.191000 | 3.30e-01 |
| VEGFR2 mediated cell proliferation | 15 | 2.01e-01 | -0.191000 | 3.81e-01 |
| Chromosome Maintenance | 73 | 4.89e-03 | -0.191000 | 2.50e-02 |
| Oxidative Stress Induced Senescence | 57 | 1.30e-02 | 0.190000 | 5.24e-02 |
| Peptide chain elongation | 87 | 2.33e-03 | 0.189000 | 1.36e-02 |
| Translesion Synthesis by POLH | 17 | 1.79e-01 | -0.188000 | 3.53e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 19 | 1.56e-01 | -0.188000 | 3.21e-01 |
| Lagging Strand Synthesis | 18 | 1.67e-01 | -0.188000 | 3.37e-01 |
| Metabolism of steroids | 102 | 1.07e-03 | -0.188000 | 7.16e-03 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 30 | 7.60e-02 | 0.187000 | 1.97e-01 |
| Metabolism of fat-soluble vitamins | 22 | 1.29e-01 | 0.187000 | 2.83e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 1.70e-01 | -0.187000 | 3.41e-01 |
| Signaling by Hedgehog | 112 | 6.69e-04 | -0.186000 | 4.84e-03 |
| Oncogene Induced Senescence | 27 | 9.39e-02 | 0.186000 | 2.23e-01 |
| RHOV GTPase cycle | 29 | 8.26e-02 | 0.186000 | 2.08e-01 |
| PINK1-PRKN Mediated Mitophagy | 21 | 1.40e-01 | -0.186000 | 2.99e-01 |
| SHC1 events in ERBB2 signaling | 11 | 2.86e-01 | -0.186000 | 4.80e-01 |
| Mitochondrial tRNA aminoacylation | 15 | 2.15e-01 | -0.185000 | 3.95e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 2.32e-01 | -0.185000 | 4.15e-01 |
| Signaling by NTRK3 (TRKC) | 12 | 2.68e-01 | -0.185000 | 4.58e-01 |
| RHOQ GTPase cycle | 48 | 2.71e-02 | 0.185000 | 9.31e-02 |
| HIV Life Cycle | 148 | 1.23e-04 | -0.183000 | 1.07e-03 |
| PKA activation | 12 | 2.74e-01 | 0.183000 | 4.66e-01 |
| RHOF GTPase cycle | 30 | 8.37e-02 | 0.183000 | 2.09e-01 |
| Pre-NOTCH Processing in Golgi | 16 | 2.07e-01 | 0.182000 | 3.85e-01 |
| Signaling by WNT in cancer | 19 | 1.70e-01 | 0.182000 | 3.41e-01 |
| XBP1(S) activates chaperone genes | 41 | 4.50e-02 | -0.181000 | 1.37e-01 |
| Downstream signaling of activated FGFR1 | 13 | 2.59e-01 | 0.181000 | 4.50e-01 |
| Nucleotide catabolism | 25 | 1.18e-01 | -0.181000 | 2.68e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 20 | 1.63e-01 | -0.180000 | 3.32e-01 |
| Aggrephagy | 30 | 8.79e-02 | -0.180000 | 2.15e-01 |
| RUNX3 regulates p14-ARF | 10 | 3.24e-01 | 0.180000 | 5.26e-01 |
| Phospholipid metabolism | 148 | 1.63e-04 | 0.180000 | 1.36e-03 |
| MicroRNA (miRNA) biogenesis | 24 | 1.27e-01 | -0.180000 | 2.81e-01 |
| Pentose phosphate pathway | 13 | 2.61e-01 | -0.180000 | 4.53e-01 |
| Nuclear Receptor transcription pathway | 30 | 8.87e-02 | 0.180000 | 2.15e-01 |
| CaM pathway | 24 | 1.29e-01 | 0.179000 | 2.83e-01 |
| Calmodulin induced events | 24 | 1.29e-01 | 0.179000 | 2.83e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 21 | 1.56e-01 | 0.179000 | 3.21e-01 |
| Nicotinamide salvaging | 13 | 2.65e-01 | 0.179000 | 4.55e-01 |
| Leading Strand Synthesis | 13 | 2.66e-01 | -0.178000 | 4.56e-01 |
| Polymerase switching | 13 | 2.66e-01 | -0.178000 | 4.56e-01 |
| PI3K/AKT Signaling in Cancer | 51 | 2.82e-02 | 0.178000 | 9.50e-02 |
| RAC3 GTPase cycle | 71 | 9.80e-03 | 0.178000 | 4.23e-02 |
| MECP2 regulates neuronal receptors and channels | 10 | 3.31e-01 | 0.177000 | 5.34e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 48 | 3.36e-02 | 0.177000 | 1.09e-01 |
| Leishmania parasite growth and survival | 48 | 3.36e-02 | 0.177000 | 1.09e-01 |
| Cytosolic iron-sulfur cluster assembly | 11 | 3.09e-01 | -0.177000 | 5.06e-01 |
| Glucose metabolism | 76 | 7.75e-03 | -0.177000 | 3.44e-02 |
| RHO GTPases Activate NADPH Oxidases | 19 | 1.84e-01 | 0.176000 | 3.60e-01 |
| Processing of Capped Intronless Pre-mRNA | 27 | 1.16e-01 | -0.175000 | 2.65e-01 |
| Signaling by SCF-KIT | 34 | 7.78e-02 | 0.175000 | 1.99e-01 |
| Formation of a pool of free 40S subunits | 98 | 2.83e-03 | 0.175000 | 1.60e-02 |
| Neddylation | 198 | 2.40e-05 | -0.175000 | 2.43e-04 |
| Downstream signal transduction | 25 | 1.31e-01 | 0.175000 | 2.86e-01 |
| Acyl chain remodelling of PC | 10 | 3.41e-01 | 0.174000 | 5.44e-01 |
| G2/M Transition | 159 | 1.61e-04 | -0.174000 | 1.35e-03 |
| Negative regulation of the PI3K/AKT network | 58 | 2.21e-02 | 0.174000 | 7.89e-02 |
| Base-Excision Repair, AP Site Formation | 16 | 2.31e-01 | -0.173000 | 4.14e-01 |
| MyD88 deficiency (TLR2/4) | 14 | 2.63e-01 | 0.173000 | 4.54e-01 |
| Glycogen synthesis | 10 | 3.45e-01 | -0.172000 | 5.46e-01 |
| IRAK2 mediated activation of TAK1 complex | 10 | 3.45e-01 | 0.172000 | 5.46e-01 |
| Activation of IRF3, IRF7 mediated by TBK1, IKBKE | 17 | 2.19e-01 | 0.172000 | 4.00e-01 |
| Maturation of nucleoprotein 9683610 | 11 | 3.23e-01 | 0.172000 | 5.26e-01 |
| RAC2 GTPase cycle | 73 | 1.12e-02 | 0.172000 | 4.62e-02 |
| GPCR downstream signalling | 213 | 1.73e-05 | 0.172000 | 1.80e-04 |
| Viral mRNA Translation | 87 | 5.82e-03 | 0.171000 | 2.76e-02 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 34 | 8.53e-02 | 0.171000 | 2.12e-01 |
| Resolution of Abasic Sites (AP sites) | 33 | 9.07e-02 | -0.170000 | 2.18e-01 |
| mRNA Splicing | 208 | 2.62e-05 | -0.170000 | 2.61e-04 |
| Base Excision Repair | 40 | 6.39e-02 | -0.169000 | 1.72e-01 |
| Mitotic G2-G2/M phases | 160 | 2.30e-04 | -0.169000 | 1.87e-03 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 34 | 8.81e-02 | -0.169000 | 2.15e-01 |
| Eukaryotic Translation Elongation | 90 | 5.89e-03 | 0.168000 | 2.78e-02 |
| Activation of ATR in response to replication stress | 21 | 1.82e-01 | -0.168000 | 3.57e-01 |
| Cytosolic sulfonation of small molecules | 11 | 3.35e-01 | 0.168000 | 5.38e-01 |
| Ca-dependent events | 26 | 1.38e-01 | 0.168000 | 2.98e-01 |
| mRNA Splicing - Major Pathway | 200 | 4.58e-05 | -0.168000 | 4.37e-04 |
| Beta-oxidation of very long chain fatty acids | 10 | 3.59e-01 | -0.168000 | 5.57e-01 |
| Termination of translesion DNA synthesis | 27 | 1.35e-01 | -0.166000 | 2.93e-01 |
| Transcriptional Regulation by MECP2 | 39 | 7.40e-02 | 0.165000 | 1.93e-01 |
| DNA strand elongation | 21 | 1.91e-01 | -0.165000 | 3.67e-01 |
| CD28 dependent PI3K/Akt signaling | 20 | 2.02e-01 | 0.165000 | 3.82e-01 |
| Death Receptor Signaling | 123 | 1.64e-03 | 0.165000 | 1.03e-02 |
| Signaling by CSF3 (G-CSF) | 29 | 1.25e-01 | 0.165000 | 2.78e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 67 | 2.06e-02 | -0.164000 | 7.48e-02 |
| G2/M DNA damage checkpoint | 50 | 4.55e-02 | -0.164000 | 1.38e-01 |
| SUMOylation of transcription cofactors | 40 | 7.39e-02 | 0.163000 | 1.93e-01 |
| Interleukin-1 family signaling | 124 | 1.75e-03 | -0.163000 | 1.09e-02 |
| TCR signaling | 98 | 5.61e-03 | -0.162000 | 2.69e-02 |
| Dual Incision in GG-NER | 38 | 8.38e-02 | -0.162000 | 2.09e-01 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 11 | 3.53e-01 | -0.162000 | 5.52e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 108 | 3.74e-03 | 0.162000 | 2.02e-02 |
| Programmed Cell Death | 178 | 2.11e-04 | -0.162000 | 1.73e-03 |
| PKA activation in glucagon signalling | 11 | 3.55e-01 | 0.161000 | 5.54e-01 |
| RHOBTB2 GTPase cycle | 23 | 1.82e-01 | 0.161000 | 3.57e-01 |
| Activation of BH3-only proteins | 27 | 1.49e-01 | -0.161000 | 3.10e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 98 | 6.09e-03 | 0.161000 | 2.83e-02 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 51 | 4.79e-02 | 0.160000 | 1.43e-01 |
| Semaphorin interactions | 47 | 5.83e-02 | 0.160000 | 1.61e-01 |
| Asparagine N-linked glycosylation | 250 | 1.54e-05 | -0.160000 | 1.61e-04 |
| tRNA processing in the nucleus | 56 | 3.91e-02 | -0.160000 | 1.23e-01 |
| Signaling by ALK | 21 | 2.07e-01 | 0.159000 | 3.85e-01 |
| Metabolism of porphyrins | 19 | 2.30e-01 | -0.159000 | 4.13e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 3.40e-01 | 0.159000 | 5.43e-01 |
| Triglyceride metabolism | 20 | 2.19e-01 | -0.159000 | 4.00e-01 |
| DAG and IP3 signaling | 28 | 1.47e-01 | 0.158000 | 3.08e-01 |
| COPII-mediated vesicle transport | 58 | 3.78e-02 | -0.158000 | 1.19e-01 |
| Apoptosis | 149 | 9.21e-04 | -0.158000 | 6.34e-03 |
| HS-GAG degradation | 14 | 3.07e-01 | 0.158000 | 5.05e-01 |
| Signalling to RAS | 14 | 3.10e-01 | -0.157000 | 5.08e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 2.94e-01 | -0.157000 | 4.88e-01 |
| Insulin processing | 16 | 2.80e-01 | 0.156000 | 4.73e-01 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 99 | 7.66e-03 | 0.155000 | 3.41e-02 |
| Gap junction trafficking | 19 | 2.43e-01 | -0.155000 | 4.32e-01 |
| Diseases of metabolism | 133 | 2.11e-03 | -0.155000 | 1.25e-02 |
| Plasma lipoprotein assembly | 12 | 3.53e-01 | 0.155000 | 5.52e-01 |
| FOXO-mediated transcription | 45 | 7.29e-02 | 0.155000 | 1.92e-01 |
| FLT3 Signaling | 32 | 1.31e-01 | 0.154000 | 2.86e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 22 | 2.12e-01 | -0.154000 | 3.92e-01 |
| IRAK4 deficiency (TLR2/4) | 15 | 3.03e-01 | 0.154000 | 5.02e-01 |
| Diseases associated with glycosaminoglycan metabolism | 19 | 2.49e-01 | 0.153000 | 4.39e-01 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 109 | 6.04e-03 | 0.153000 | 2.83e-02 |
| Signaling by GPCR | 229 | 7.67e-05 | 0.152000 | 7.06e-04 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 3.25e-01 | 0.152000 | 5.26e-01 |
| PTEN Regulation | 130 | 2.87e-03 | -0.152000 | 1.62e-02 |
| Complement cascade | 19 | 2.52e-01 | 0.152000 | 4.43e-01 |
| Formation of RNA Pol II elongation complex | 56 | 5.02e-02 | -0.151000 | 1.47e-01 |
| RNA Polymerase II Transcription Elongation | 56 | 5.02e-02 | -0.151000 | 1.47e-01 |
| Selective autophagy | 66 | 3.38e-02 | -0.151000 | 1.09e-01 |
| Lysosome Vesicle Biogenesis | 32 | 1.39e-01 | -0.151000 | 2.99e-01 |
| Stimuli-sensing channels | 44 | 8.37e-02 | 0.151000 | 2.09e-01 |
| RNA Polymerase II Pre-transcription Events | 74 | 2.52e-02 | -0.151000 | 8.77e-02 |
| Selenocysteine synthesis | 90 | 1.37e-02 | 0.151000 | 5.45e-02 |
| DNA Damage/Telomere Stress Induced Senescence | 23 | 2.12e-01 | 0.150000 | 3.92e-01 |
| Signaling by NOTCH3 | 33 | 1.37e-01 | 0.150000 | 2.96e-01 |
| Signaling by NOTCH1 | 59 | 4.71e-02 | 0.150000 | 1.42e-01 |
| Beta-catenin phosphorylation cascade | 14 | 3.37e-01 | 0.148000 | 5.40e-01 |
| DCC mediated attractive signaling | 10 | 4.18e-01 | 0.148000 | 6.20e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 3.96e-01 | -0.148000 | 5.99e-01 |
| alpha-linolenic acid (ALA) metabolism | 11 | 3.96e-01 | -0.148000 | 5.99e-01 |
| ER to Golgi Anterograde Transport | 125 | 4.48e-03 | -0.148000 | 2.33e-02 |
| Uptake and actions of bacterial toxins | 17 | 2.93e-01 | 0.147000 | 4.88e-01 |
| G beta:gamma signalling through CDC42 | 13 | 3.58e-01 | -0.147000 | 5.56e-01 |
| Metabolism of amino acids and derivatives | 266 | 4.16e-05 | -0.147000 | 4.03e-04 |
| NCAM signaling for neurite out-growth | 25 | 2.06e-01 | 0.146000 | 3.85e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 41 | 1.06e-01 | -0.146000 | 2.48e-01 |
| Diseases of carbohydrate metabolism | 24 | 2.18e-01 | -0.145000 | 3.98e-01 |
| Intraflagellar transport | 39 | 1.18e-01 | -0.145000 | 2.67e-01 |
| Interleukin-37 signaling | 15 | 3.32e-01 | 0.145000 | 5.35e-01 |
| Signaling by PDGF | 35 | 1.40e-01 | 0.144000 | 2.99e-01 |
| Metabolism of RNA | 689 | 2.51e-10 | -0.144000 | 4.76e-09 |
| Impaired BRCA2 binding to PALB2 | 19 | 2.80e-01 | 0.143000 | 4.73e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 1.78e-02 | 0.142000 | 6.58e-02 |
| Toll-like Receptor Cascades | 144 | 3.27e-03 | 0.142000 | 1.81e-02 |
| Activation of gene expression by SREBF (SREBP) | 41 | 1.15e-01 | -0.142000 | 2.64e-01 |
| SUMO E3 ligases SUMOylate target proteins | 146 | 3.09e-03 | 0.142000 | 1.73e-02 |
| Signaling by NTRK1 (TRKA) | 86 | 2.29e-02 | 0.142000 | 8.13e-02 |
| Unfolded Protein Response (UPR) | 81 | 2.74e-02 | -0.142000 | 9.35e-02 |
| Gap junction trafficking and regulation | 21 | 2.62e-01 | -0.141000 | 4.53e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 31 | 1.73e-01 | -0.141000 | 3.45e-01 |
| Regulation of KIT signaling | 12 | 3.97e-01 | 0.141000 | 5.99e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 2.87e-01 | 0.141000 | 4.80e-01 |
| FCERI mediated MAPK activation | 27 | 2.06e-01 | 0.141000 | 3.85e-01 |
| Signaling by NTRKs | 98 | 1.62e-02 | 0.141000 | 6.12e-02 |
| RNA Polymerase II Transcription Termination | 62 | 5.57e-02 | -0.141000 | 1.56e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 5.39e-02 | 0.141000 | 1.53e-01 |
| Nuclear signaling by ERBB4 | 18 | 3.03e-01 | 0.140000 | 5.02e-01 |
| Potential therapeutics for SARS | 82 | 2.87e-02 | 0.140000 | 9.63e-02 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 12 | 4.03e-01 | 0.139000 | 6.04e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 12 | 4.03e-01 | 0.139000 | 6.04e-01 |
| Metabolism of non-coding RNA | 50 | 8.85e-02 | -0.139000 | 2.15e-01 |
| snRNP Assembly | 50 | 8.85e-02 | -0.139000 | 2.15e-01 |
| Signaling by Rho GTPases | 475 | 2.70e-07 | 0.139000 | 3.61e-06 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 35 | 1.55e-01 | 0.139000 | 3.20e-01 |
| Cell-Cell communication | 74 | 3.96e-02 | 0.139000 | 1.23e-01 |
| RND2 GTPase cycle | 28 | 2.06e-01 | 0.138000 | 3.85e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 13 | 3.90e-01 | -0.138000 | 5.93e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 4.11e-01 | -0.137000 | 6.14e-01 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 42 | 1.25e-01 | -0.137000 | 2.78e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 28 | 2.11e-01 | 0.137000 | 3.90e-01 |
| Regulated Necrosis | 53 | 8.55e-02 | -0.137000 | 2.12e-01 |
| Cellular Senescence | 108 | 1.45e-02 | 0.136000 | 5.65e-02 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 488 | 3.28e-07 | 0.136000 | 4.29e-06 |
| Formation of Incision Complex in GG-NER | 42 | 1.27e-01 | -0.136000 | 2.81e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 127 | 8.42e-03 | 0.136000 | 3.68e-02 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 6.76e-02 | -0.136000 | 1.79e-01 |
| MTOR signalling | 39 | 1.44e-01 | -0.135000 | 3.03e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 37 | 1.54e-01 | -0.135000 | 3.20e-01 |
| Diseases of glycosylation | 69 | 5.23e-02 | -0.135000 | 1.51e-01 |
| VxPx cargo-targeting to cilium | 17 | 3.35e-01 | 0.135000 | 5.38e-01 |
| Regulation of TP53 Expression and Degradation | 34 | 1.74e-01 | 0.135000 | 3.46e-01 |
| Transcriptional regulation of white adipocyte differentiation | 68 | 5.55e-02 | 0.135000 | 1.55e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 31 | 1.97e-01 | -0.134000 | 3.77e-01 |
| Signaling by KIT in disease | 17 | 3.42e-01 | 0.133000 | 5.44e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 17 | 3.42e-01 | 0.133000 | 5.44e-01 |
| Metabolism | 1435 | 3.82e-16 | -0.133000 | 5.56e-14 |
| Regulation of NF-kappa B signaling | 18 | 3.30e-01 | 0.133000 | 5.34e-01 |
| SUMOylation | 152 | 4.91e-03 | 0.133000 | 2.50e-02 |
| VEGFA-VEGFR2 Pathway | 81 | 3.96e-02 | 0.133000 | 1.23e-01 |
| TCF dependent signaling in response to WNT | 119 | 1.30e-02 | -0.132000 | 5.24e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 2.36e-01 | -0.132000 | 4.20e-01 |
| Erythropoietin activates RAS | 13 | 4.11e-01 | 0.132000 | 6.14e-01 |
| Regulation of TLR by endogenous ligand | 13 | 4.12e-01 | 0.131000 | 6.14e-01 |
| Sema3A PAK dependent Axon repulsion | 14 | 3.97e-01 | -0.131000 | 5.99e-01 |
| STAT3 nuclear events downstream of ALK signaling | 10 | 4.74e-01 | 0.131000 | 6.74e-01 |
| DARPP-32 events | 21 | 3.04e-01 | 0.130000 | 5.03e-01 |
| Depolymerization of the Nuclear Lamina | 12 | 4.38e-01 | -0.129000 | 6.38e-01 |
| Regulation of expression of SLITs and ROBOs | 155 | 5.67e-03 | -0.129000 | 2.71e-02 |
| O-linked glycosylation | 38 | 1.69e-01 | -0.129000 | 3.38e-01 |
| Resolution of D-Loop Structures | 23 | 2.84e-01 | 0.129000 | 4.76e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 23 | 2.84e-01 | 0.129000 | 4.76e-01 |
| Cleavage of the damaged purine | 10 | 4.80e-01 | -0.129000 | 6.78e-01 |
| Depurination | 10 | 4.80e-01 | -0.129000 | 6.78e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 10 | 4.80e-01 | -0.129000 | 6.78e-01 |
| Bacterial Infection Pathways | 53 | 1.05e-01 | 0.129000 | 2.48e-01 |
| Signaling by TGFB family members | 84 | 4.24e-02 | 0.128000 | 1.31e-01 |
| Plasma lipoprotein remodeling | 13 | 4.24e-01 | 0.128000 | 6.24e-01 |
| Nuclear Envelope (NE) Reassembly | 62 | 8.17e-02 | -0.128000 | 2.07e-01 |
| Diseases associated with the TLR signaling cascade | 26 | 2.59e-01 | 0.128000 | 4.50e-01 |
| Diseases of Immune System | 26 | 2.59e-01 | 0.128000 | 4.50e-01 |
| Fc epsilon receptor (FCERI) signaling | 118 | 1.70e-02 | -0.128000 | 6.33e-02 |
| Signaling by TGF-beta Receptor Complex | 74 | 5.86e-02 | 0.127000 | 1.61e-01 |
| Cargo concentration in the ER | 24 | 2.81e-01 | -0.127000 | 4.74e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 12 | 4.46e-01 | 0.127000 | 6.49e-01 |
| ERK/MAPK targets | 20 | 3.26e-01 | 0.127000 | 5.28e-01 |
| Nuclear events stimulated by ALK signaling in cancer | 19 | 3.38e-01 | 0.127000 | 5.41e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 34 | 2.02e-01 | 0.127000 | 3.82e-01 |
| Fatty acid metabolism | 113 | 2.09e-02 | -0.126000 | 7.55e-02 |
| FCGR3A-mediated phagocytosis | 53 | 1.13e-01 | 0.126000 | 2.61e-01 |
| Leishmania phagocytosis | 53 | 1.13e-01 | 0.126000 | 2.61e-01 |
| Parasite infection | 53 | 1.13e-01 | 0.126000 | 2.61e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 75 | 5.98e-02 | 0.126000 | 1.63e-01 |
| Maturation of nucleoprotein 9694631 | 15 | 3.99e-01 | 0.126000 | 6.01e-01 |
| Miscellaneous transport and binding events | 16 | 3.84e-01 | 0.126000 | 5.89e-01 |
| Interleukin-4 and Interleukin-13 signaling | 64 | 8.59e-02 | 0.124000 | 2.12e-01 |
| RAB geranylgeranylation | 47 | 1.41e-01 | -0.124000 | 3.00e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 96 | 3.58e-02 | 0.124000 | 1.14e-01 |
| Vpr-mediated nuclear import of PICs | 38 | 1.86e-01 | -0.124000 | 3.62e-01 |
| M Phase | 294 | 2.82e-04 | -0.124000 | 2.25e-03 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 33 | 2.21e-01 | 0.123000 | 4.03e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 49 | 1.38e-01 | 0.123000 | 2.98e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 274 | 5.45e-04 | -0.122000 | 4.07e-03 |
| Cap-dependent Translation Initiation | 116 | 2.35e-02 | 0.122000 | 8.29e-02 |
| Eukaryotic Translation Initiation | 116 | 2.35e-02 | 0.122000 | 8.29e-02 |
| Basigin interactions | 17 | 3.85e-01 | -0.122000 | 5.90e-01 |
| Intrinsic Pathway for Apoptosis | 50 | 1.41e-01 | -0.121000 | 2.99e-01 |
| Processing of SMDT1 | 14 | 4.37e-01 | -0.120000 | 6.37e-01 |
| SARS-CoV-2 modulates host translation machinery | 47 | 1.55e-01 | -0.120000 | 3.20e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 15 | 4.21e-01 | -0.120000 | 6.23e-01 |
| Nucleotide salvage | 20 | 3.56e-01 | -0.119000 | 5.55e-01 |
| G alpha (s) signalling events | 50 | 1.45e-01 | 0.119000 | 3.06e-01 |
| VEGFR2 mediated vascular permeability | 23 | 3.23e-01 | 0.119000 | 5.26e-01 |
| G-protein activation | 14 | 4.42e-01 | -0.119000 | 6.42e-01 |
| Interactions of Vpr with host cellular proteins | 41 | 1.90e-01 | -0.118000 | 3.66e-01 |
| G0 and Early G1 | 15 | 4.28e-01 | 0.118000 | 6.28e-01 |
| Oncogenic MAPK signaling | 68 | 9.26e-02 | 0.118000 | 2.21e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 12 | 4.80e-01 | -0.118000 | 6.78e-01 |
| ERKs are inactivated | 12 | 4.81e-01 | -0.118000 | 6.78e-01 |
| G beta:gamma signalling through BTK | 11 | 5.00e-01 | -0.117000 | 6.95e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 93 | 5.20e-02 | 0.117000 | 1.50e-01 |
| Biological oxidations | 88 | 5.94e-02 | -0.117000 | 1.63e-01 |
| MyD88-independent TLR4 cascade | 100 | 4.47e-02 | 0.116000 | 1.36e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 100 | 4.47e-02 | 0.116000 | 1.36e-01 |
| IRAK1 recruits IKK complex | 14 | 4.52e-01 | -0.116000 | 6.54e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 4.52e-01 | -0.116000 | 6.54e-01 |
| CTNNB1 S33 mutants aren’t phosphorylated | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| CTNNB1 S37 mutants aren’t phosphorylated | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| CTNNB1 S45 mutants aren’t phosphorylated | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| CTNNB1 T41 mutants aren’t phosphorylated | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| Signaling by CTNNB1 phospho-site mutants | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| Signaling by GSK3beta mutants | 13 | 4.69e-01 | 0.116000 | 6.68e-01 |
| RUNX2 regulates bone development | 16 | 4.22e-01 | 0.116000 | 6.23e-01 |
| TNFR1-induced NF-kappa-B signaling pathway | 31 | 2.65e-01 | 0.116000 | 4.55e-01 |
| Regulated proteolysis of p75NTR | 10 | 5.26e-01 | -0.116000 | 7.18e-01 |
| Golgi-to-ER retrograde transport | 98 | 4.85e-02 | -0.116000 | 1.45e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 48 | 1.67e-01 | 0.116000 | 3.36e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 48 | 1.67e-01 | 0.116000 | 3.36e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 48 | 1.67e-01 | 0.116000 | 3.36e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 48 | 1.67e-01 | 0.116000 | 3.36e-01 |
| Signaling by NOTCH1 in Cancer | 48 | 1.67e-01 | 0.116000 | 3.36e-01 |
| RAF/MAP kinase cascade | 169 | 1.03e-02 | -0.115000 | 4.40e-02 |
| rRNA processing in the nucleus and cytosol | 182 | 7.94e-03 | -0.115000 | 3.51e-02 |
| O-linked glycosylation of mucins | 27 | 3.06e-01 | -0.114000 | 5.03e-01 |
| Transcriptional Regulation by VENTX | 34 | 2.51e-01 | 0.114000 | 4.41e-01 |
| Defective pyroptosis | 13 | 4.80e-01 | 0.113000 | 6.78e-01 |
| Zinc transporters | 11 | 5.16e-01 | -0.113000 | 7.08e-01 |
| Deadenylation-dependent mRNA decay | 50 | 1.68e-01 | -0.113000 | 3.37e-01 |
| Opioid Signalling | 61 | 1.28e-01 | 0.113000 | 2.83e-01 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | 10 | 5.38e-01 | 0.113000 | 7.27e-01 |
| PERK regulates gene expression | 30 | 2.88e-01 | -0.112000 | 4.81e-01 |
| Gap junction assembly | 10 | 5.39e-01 | -0.112000 | 7.27e-01 |
| Transport of connexons to the plasma membrane | 10 | 5.39e-01 | -0.112000 | 7.27e-01 |
| Visual phototransduction | 43 | 2.05e-01 | 0.112000 | 3.85e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 38 | 2.34e-01 | 0.112000 | 4.18e-01 |
| Signaling by PTK6 | 38 | 2.34e-01 | 0.112000 | 4.18e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 91 | 6.66e-02 | 0.111000 | 1.77e-01 |
| Formation of WDR5-containing histone-modifying complexes | 40 | 2.23e-01 | 0.111000 | 4.05e-01 |
| Mitochondrial biogenesis | 82 | 8.19e-02 | -0.111000 | 2.07e-01 |
| Ephrin signaling | 13 | 4.87e-01 | 0.111000 | 6.84e-01 |
| Regulation of TP53 Degradation | 33 | 2.71e-01 | 0.111000 | 4.62e-01 |
| Inwardly rectifying K+ channels | 12 | 5.06e-01 | -0.111000 | 7.01e-01 |
| G alpha (i) signalling events | 104 | 5.24e-02 | 0.110000 | 1.51e-01 |
| Metabolism of proteins | 1358 | 4.17e-11 | -0.110000 | 1.00e-09 |
| Toll Like Receptor 3 (TLR3) Cascade | 95 | 6.39e-02 | 0.110000 | 1.72e-01 |
| MyD88 cascade initiated on plasma membrane | 87 | 7.65e-02 | 0.110000 | 1.97e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 87 | 7.65e-02 | 0.110000 | 1.97e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 87 | 7.65e-02 | 0.110000 | 1.97e-01 |
| MAPK1/MAPK3 signaling | 173 | 1.33e-02 | -0.109000 | 5.33e-02 |
| Eukaryotic Translation Termination | 91 | 7.19e-02 | 0.109000 | 1.90e-01 |
| HSF1 activation | 23 | 3.66e-01 | -0.109000 | 5.65e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 101 | 5.97e-02 | 0.109000 | 1.63e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 101 | 5.97e-02 | 0.109000 | 1.63e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 101 | 5.97e-02 | 0.109000 | 1.63e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 101 | 5.97e-02 | 0.109000 | 1.63e-01 |
| Metabolism of water-soluble vitamins and cofactors | 88 | 7.88e-02 | -0.109000 | 2.01e-01 |
| Transport to the Golgi and subsequent modification | 146 | 2.43e-02 | -0.108000 | 8.55e-02 |
| Calnexin/calreticulin cycle | 25 | 3.49e-01 | -0.108000 | 5.49e-01 |
| Ribavirin ADME | 10 | 5.55e-01 | 0.108000 | 7.41e-01 |
| MyD88 dependent cascade initiated on endosome | 92 | 7.52e-02 | 0.108000 | 1.96e-01 |
| Cardiac conduction | 42 | 2.29e-01 | 0.107000 | 4.12e-01 |
| Regulation of TP53 Activity through Acetylation | 29 | 3.20e-01 | 0.107000 | 5.21e-01 |
| SLC-mediated transmembrane transport | 115 | 4.91e-02 | 0.107000 | 1.45e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 54 | 1.77e-01 | -0.106000 | 3.50e-01 |
| Signaling by BRAF and RAF1 fusions | 54 | 1.78e-01 | 0.106000 | 3.51e-01 |
| Selenoamino acid metabolism | 101 | 6.63e-02 | 0.106000 | 1.77e-01 |
| VLDLR internalisation and degradation | 15 | 4.78e-01 | -0.106000 | 6.78e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 17 | 4.50e-01 | 0.106000 | 6.53e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 4.66e-01 | 0.105000 | 6.68e-01 |
| Cell junction organization | 49 | 2.03e-01 | 0.105000 | 3.83e-01 |
| Signal Transduction | 1476 | 6.68e-11 | 0.105000 | 1.51e-09 |
| Cell Cycle | 482 | 9.27e-05 | -0.105000 | 8.42e-04 |
| TP53 Regulates Transcription of Cell Cycle Genes | 35 | 2.83e-01 | 0.105000 | 4.75e-01 |
| Signaling by Insulin receptor | 48 | 2.09e-01 | -0.105000 | 3.88e-01 |
| Signaling by FGFR2 | 49 | 2.04e-01 | -0.105000 | 3.85e-01 |
| Formation of the cornified envelope | 16 | 4.69e-01 | -0.105000 | 6.68e-01 |
| Keratinization | 16 | 4.69e-01 | -0.105000 | 6.68e-01 |
| Negative regulation of FLT3 | 11 | 5.49e-01 | 0.104000 | 7.36e-01 |
| RAF activation | 32 | 3.07e-01 | -0.104000 | 5.05e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 17 | 4.56e-01 | -0.104000 | 6.58e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 11 | 5.50e-01 | 0.104000 | 7.37e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 58 | 1.71e-01 | -0.104000 | 3.42e-01 |
| Macroautophagy | 118 | 5.21e-02 | -0.104000 | 1.50e-01 |
| SUMOylation of intracellular receptors | 23 | 3.89e-01 | 0.104000 | 5.93e-01 |
| RHO GTPases activate CIT | 14 | 5.03e-01 | -0.103000 | 6.97e-01 |
| Signaling by VEGF | 86 | 9.81e-02 | 0.103000 | 2.32e-01 |
| Intra-Golgi traffic | 39 | 2.65e-01 | 0.103000 | 4.55e-01 |
| Fanconi Anemia Pathway | 28 | 3.45e-01 | -0.103000 | 5.46e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 20 | 4.25e-01 | 0.103000 | 6.25e-01 |
| MAP2K and MAPK activation | 32 | 3.14e-01 | -0.103000 | 5.14e-01 |
| Golgi Associated Vesicle Biogenesis | 52 | 2.00e-01 | -0.103000 | 3.80e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 56 | 1.84e-01 | 0.103000 | 3.60e-01 |
| Collagen formation | 31 | 3.24e-01 | -0.102000 | 5.26e-01 |
| Signaling by NTRK2 (TRKB) | 18 | 4.53e-01 | 0.102000 | 6.55e-01 |
| Peptide ligand-binding receptors | 33 | 3.11e-01 | -0.102000 | 5.10e-01 |
| Condensation of Prophase Chromosomes | 11 | 5.60e-01 | 0.102000 | 7.44e-01 |
| Deactivation of the beta-catenin transactivating complex | 30 | 3.37e-01 | 0.101000 | 5.40e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 29 | 3.46e-01 | -0.101000 | 5.46e-01 |
| Ovarian tumor domain proteases | 33 | 3.16e-01 | 0.101000 | 5.17e-01 |
| TNF signaling | 52 | 2.09e-01 | 0.101000 | 3.88e-01 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 5.82e-01 | -0.101000 | 7.56e-01 |
| p75NTR signals via NF-kB | 14 | 5.15e-01 | 0.101000 | 7.07e-01 |
| RHOD GTPase cycle | 40 | 2.74e-01 | 0.100000 | 4.66e-01 |
| Trafficking and processing of endosomal TLR | 10 | 5.84e-01 | 0.100000 | 7.57e-01 |
| Potassium Channels | 21 | 4.29e-01 | -0.099700 | 6.29e-01 |
| Metabolism of vitamins and cofactors | 125 | 5.53e-02 | -0.099500 | 1.55e-01 |
| RHOG GTPase cycle | 59 | 1.88e-01 | 0.099200 | 3.65e-01 |
| trans-Golgi Network Vesicle Budding | 67 | 1.61e-01 | -0.099100 | 3.30e-01 |
| Degradation of the extracellular matrix | 51 | 2.22e-01 | 0.098900 | 4.04e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 7.02e-02 | 0.098900 | 1.85e-01 |
| Nonsense-Mediated Decay (NMD) | 113 | 7.02e-02 | 0.098900 | 1.85e-01 |
| Signaling by Nuclear Receptors | 176 | 2.46e-02 | 0.098600 | 8.59e-02 |
| DNA Damage Bypass | 41 | 2.80e-01 | -0.097600 | 4.73e-01 |
| Interferon Signaling | 211 | 1.53e-02 | 0.097300 | 5.84e-02 |
| N-Glycan antennae elongation | 11 | 5.77e-01 | 0.097100 | 7.53e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 11 | 5.78e-01 | -0.096800 | 7.54e-01 |
| Cytoprotection by HMOX1 | 58 | 2.05e-01 | -0.096400 | 3.85e-01 |
| Cell Cycle, Mitotic | 392 | 1.21e-03 | -0.096100 | 7.82e-03 |
| RHOH GTPase cycle | 29 | 3.73e-01 | 0.095700 | 5.74e-01 |
| Platelet degranulation | 76 | 1.52e-01 | -0.095300 | 3.16e-01 |
| Neurotransmitter release cycle | 21 | 4.51e-01 | 0.095200 | 6.53e-01 |
| Glycolysis | 61 | 2.00e-01 | -0.095100 | 3.80e-01 |
| Signaling by FLT3 ITD and TKD mutants | 14 | 5.38e-01 | 0.095000 | 7.27e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 17 | 4.99e-01 | -0.094700 | 6.95e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 5.72e-01 | 0.094300 | 7.52e-01 |
| Disorders of Developmental Biology | 11 | 5.89e-01 | 0.094200 | 7.58e-01 |
| Disorders of Nervous System Development | 11 | 5.89e-01 | 0.094200 | 7.58e-01 |
| Loss of function of MECP2 in Rett syndrome | 11 | 5.89e-01 | 0.094200 | 7.58e-01 |
| Pervasive developmental disorders | 11 | 5.89e-01 | 0.094200 | 7.58e-01 |
| Infection with Mycobacterium tuberculosis | 24 | 4.27e-01 | 0.093800 | 6.27e-01 |
| Factors involved in megakaryocyte development and platelet production | 92 | 1.21e-01 | 0.093800 | 2.72e-01 |
| Signaling by MET | 51 | 2.48e-01 | 0.093700 | 4.37e-01 |
| Signaling by FGFR1 | 32 | 3.62e-01 | 0.093300 | 5.60e-01 |
| Branched-chain amino acid catabolism | 21 | 4.60e-01 | -0.093200 | 6.63e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 11 | 5.96e-01 | 0.092400 | 7.65e-01 |
| p75NTR recruits signalling complexes | 11 | 5.97e-01 | 0.092100 | 7.65e-01 |
| Listeria monocytogenes entry into host cells | 17 | 5.11e-01 | 0.092000 | 7.05e-01 |
| Transcriptional activation of mitochondrial biogenesis | 47 | 2.76e-01 | 0.092000 | 4.69e-01 |
| Interleukin-17 signaling | 61 | 2.15e-01 | 0.091900 | 3.95e-01 |
| Carnitine metabolism | 11 | 5.99e-01 | 0.091600 | 7.65e-01 |
| Response to elevated platelet cytosolic Ca2+ | 80 | 1.58e-01 | -0.091400 | 3.25e-01 |
| EPHB-mediated forward signaling | 33 | 3.66e-01 | -0.091000 | 5.65e-01 |
| DNA Repair | 245 | 1.48e-02 | -0.090900 | 5.74e-02 |
| Keratan sulfate biosynthesis | 14 | 5.59e-01 | -0.090300 | 7.44e-01 |
| Regulation of lipid metabolism by PPARalpha | 98 | 1.24e-01 | 0.090100 | 2.77e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 25 | 4.36e-01 | -0.090100 | 6.37e-01 |
| Leishmania infection | 122 | 8.73e-02 | 0.089900 | 2.15e-01 |
| Parasitic Infection Pathways | 122 | 8.73e-02 | 0.089900 | 2.15e-01 |
| Sensory Perception | 77 | 1.75e-01 | 0.089500 | 3.47e-01 |
| Transcriptional Regulation by TP53 | 318 | 6.77e-03 | -0.088900 | 3.11e-02 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 20 | 4.93e-01 | 0.088700 | 6.88e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 20 | 4.93e-01 | 0.088700 | 6.88e-01 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 20 | 4.93e-01 | 0.088700 | 6.88e-01 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | 20 | 4.93e-01 | 0.088700 | 6.88e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 20 | 4.93e-01 | 0.088700 | 6.88e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 28 | 4.19e-01 | 0.088300 | 6.21e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 71 | 1.99e-01 | -0.088200 | 3.80e-01 |
| PPARA activates gene expression | 96 | 1.37e-01 | 0.087900 | 2.97e-01 |
| PKR-mediated signaling | 59 | 2.43e-01 | -0.087900 | 4.32e-01 |
| Signaling by ERBB4 | 34 | 3.76e-01 | 0.087900 | 5.78e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 172 | 4.77e-02 | -0.087900 | 1.43e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 12 | 5.98e-01 | 0.087800 | 7.65e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 5.99e-01 | 0.087700 | 7.65e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 5.99e-01 | 0.087700 | 7.65e-01 |
| IKK complex recruitment mediated by RIP1 | 23 | 4.69e-01 | 0.087300 | 6.68e-01 |
| Recycling pathway of L1 | 33 | 3.86e-01 | -0.087200 | 5.90e-01 |
| Influenza Viral RNA Transcription and Replication | 133 | 8.38e-02 | 0.087100 | 2.09e-01 |
| Glycogen storage diseases | 11 | 6.18e-01 | -0.086900 | 7.79e-01 |
| Translation initiation complex formation | 57 | 2.57e-01 | 0.086800 | 4.49e-01 |
| GAB1 signalosome | 10 | 6.35e-01 | -0.086800 | 7.94e-01 |
| Viral Messenger RNA Synthesis | 43 | 3.30e-01 | -0.085900 | 5.34e-01 |
| Negative epigenetic regulation of rRNA expression | 42 | 3.38e-01 | -0.085500 | 5.41e-01 |
| Effects of PIP2 hydrolysis | 19 | 5.21e-01 | -0.085100 | 7.14e-01 |
| RHO GTPases Activate Formins | 99 | 1.47e-01 | -0.084500 | 3.08e-01 |
| Signaling by WNT | 182 | 5.04e-02 | -0.084400 | 1.47e-01 |
| Fatty acyl-CoA biosynthesis | 24 | 4.75e-01 | -0.084300 | 6.74e-01 |
| Deubiquitination | 207 | 3.82e-02 | -0.083900 | 1.20e-01 |
| MAP kinase activation | 59 | 2.66e-01 | 0.083900 | 4.56e-01 |
| EPH-Ephrin signaling | 62 | 2.54e-01 | -0.083800 | 4.45e-01 |
| SARS-CoV-1 modulates host translation machinery | 36 | 3.85e-01 | 0.083700 | 5.90e-01 |
| Endogenous sterols | 13 | 6.02e-01 | -0.083600 | 7.67e-01 |
| Kinesins | 29 | 4.37e-01 | -0.083500 | 6.37e-01 |
| Sema4D in semaphorin signaling | 18 | 5.41e-01 | 0.083300 | 7.28e-01 |
| Signaling by FGFR in disease | 42 | 3.53e-01 | 0.082900 | 5.52e-01 |
| Synthesis of bile acids and bile salts | 17 | 5.55e-01 | 0.082800 | 7.40e-01 |
| Ribosomal scanning and start codon recognition | 57 | 2.82e-01 | 0.082500 | 4.75e-01 |
| Ub-specific processing proteases | 141 | 9.20e-02 | -0.082400 | 2.21e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 109 | 1.41e-01 | 0.081900 | 2.99e-01 |
| Clathrin-mediated endocytosis | 106 | 1.47e-01 | -0.081800 | 3.08e-01 |
| NS1 Mediated Effects on Host Pathways | 39 | 3.78e-01 | 0.081700 | 5.81e-01 |
| Metalloprotease DUBs | 16 | 5.74e-01 | -0.081200 | 7.52e-01 |
| Thrombin signalling through proteinase activated receptors (PARs) | 20 | 5.31e-01 | 0.080900 | 7.21e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 10 | 6.58e-01 | -0.080800 | 8.05e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 20 | 5.32e-01 | -0.080700 | 7.22e-01 |
| Signaling by Receptor Tyrosine Kinases | 337 | 1.16e-02 | 0.080600 | 4.76e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 11 | 6.47e-01 | 0.079800 | 8.01e-01 |
| NoRC negatively regulates rRNA expression | 40 | 3.83e-01 | -0.079800 | 5.88e-01 |
| G alpha (q) signalling events | 76 | 2.31e-01 | 0.079600 | 4.14e-01 |
| ADP signalling through P2Y purinoceptor 1 | 17 | 5.71e-01 | -0.079500 | 7.52e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 26 | 4.84e-01 | -0.079400 | 6.81e-01 |
| Mitotic Spindle Checkpoint | 81 | 2.18e-01 | -0.079300 | 3.98e-01 |
| Retrograde neurotrophin signalling | 10 | 6.65e-01 | -0.079200 | 8.09e-01 |
| Inflammasomes | 19 | 5.51e-01 | 0.079000 | 7.37e-01 |
| TBC/RABGAPs | 44 | 3.66e-01 | -0.078900 | 5.65e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 25 | 4.95e-01 | -0.078900 | 6.90e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 24 | 5.06e-01 | -0.078500 | 7.01e-01 |
| CD209 (DC-SIGN) signaling | 17 | 5.76e-01 | 0.078400 | 7.52e-01 |
| NRIF signals cell death from the nucleus | 14 | 6.13e-01 | -0.078100 | 7.76e-01 |
| Drug ADME | 41 | 3.88e-01 | -0.078000 | 5.92e-01 |
| Translesion synthesis by REV1 | 15 | 6.06e-01 | -0.077000 | 7.70e-01 |
| Impaired BRCA2 binding to RAD51 | 28 | 4.85e-01 | -0.076200 | 6.82e-01 |
| Metabolism of carbohydrates | 200 | 6.57e-02 | -0.075800 | 1.75e-01 |
| Influenza Infection | 152 | 1.09e-01 | 0.075700 | 2.54e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 50 | 3.57e-01 | 0.075500 | 5.55e-01 |
| Signaling by ROBO receptors | 186 | 7.78e-02 | -0.075300 | 1.99e-01 |
| RNA Polymerase I Promoter Clearance | 44 | 3.90e-01 | -0.075000 | 5.93e-01 |
| RNA Polymerase I Transcription | 44 | 3.90e-01 | -0.075000 | 5.93e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 14 | 6.29e-01 | -0.074600 | 7.91e-01 |
| APC truncation mutants have impaired AXIN binding | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| AXIN missense mutants destabilize the destruction complex | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| Signaling by AMER1 mutants | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| Signaling by APC mutants | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| Signaling by AXIN mutants | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| Truncations of AMER1 destabilize the destruction complex | 12 | 6.56e-01 | 0.074300 | 8.03e-01 |
| Transcriptional regulation by RUNX1 | 143 | 1.30e-01 | -0.073600 | 2.85e-01 |
| RNA Polymerase I Transcription Initiation | 40 | 4.23e-01 | -0.073300 | 6.24e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 11 | 6.75e-01 | 0.073100 | 8.14e-01 |
| SUMOylation of DNA damage response and repair proteins | 74 | 2.80e-01 | 0.072700 | 4.73e-01 |
| Scavenging by Class A Receptors | 10 | 6.91e-01 | -0.072700 | 8.24e-01 |
| STING mediated induction of host immune responses | 12 | 6.65e-01 | 0.072200 | 8.09e-01 |
| Glycogen breakdown (glycogenolysis) | 12 | 6.66e-01 | -0.072100 | 8.09e-01 |
| Cellular responses to stress | 630 | 2.52e-03 | -0.071500 | 1.46e-02 |
| Ras activation upon Ca2+ influx through NMDA receptor | 11 | 6.82e-01 | -0.071400 | 8.18e-01 |
| SLC transporter disorders | 56 | 3.57e-01 | 0.071300 | 5.55e-01 |
| Neurexins and neuroligins | 22 | 5.64e-01 | 0.071100 | 7.45e-01 |
| Loss of Nlp from mitotic centrosomes | 59 | 3.50e-01 | 0.070500 | 5.49e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 59 | 3.50e-01 | 0.070500 | 5.49e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 19 | 5.95e-01 | 0.070400 | 7.65e-01 |
| Signaling by NOTCH | 149 | 1.44e-01 | -0.069600 | 3.04e-01 |
| Apoptotic factor-mediated response | 19 | 6.00e-01 | -0.069500 | 7.66e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 15 | 6.42e-01 | -0.069400 | 8.00e-01 |
| Autophagy | 130 | 1.74e-01 | -0.069300 | 3.46e-01 |
| AKT phosphorylates targets in the cytosol | 14 | 6.55e-01 | -0.069000 | 8.03e-01 |
| Elastic fibre formation | 15 | 6.44e-01 | 0.069000 | 8.01e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 16 | 6.34e-01 | 0.068900 | 7.94e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 3.65e-01 | 0.068900 | 5.65e-01 |
| tRNA processing | 114 | 2.06e-01 | -0.068700 | 3.85e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 75 | 3.05e-01 | 0.068600 | 5.03e-01 |
| SUMOylation of DNA methylation proteins | 13 | 6.69e-01 | -0.068500 | 8.11e-01 |
| Regulation of insulin secretion | 37 | 4.72e-01 | 0.068300 | 6.72e-01 |
| Estrogen-dependent gene expression | 78 | 2.98e-01 | 0.068300 | 4.94e-01 |
| G-protein beta:gamma signalling | 24 | 5.63e-01 | 0.068200 | 7.44e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 26 | 5.48e-01 | 0.068200 | 7.35e-01 |
| Glycerophospholipid biosynthesis | 81 | 2.90e-01 | 0.068100 | 4.83e-01 |
| Regulation of Complement cascade | 17 | 6.30e-01 | 0.067600 | 7.91e-01 |
| Costimulation by the CD28 family | 52 | 4.01e-01 | 0.067400 | 6.02e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 161 | 1.42e-01 | -0.067300 | 3.01e-01 |
| Pexophagy | 11 | 7.02e-01 | 0.066600 | 8.36e-01 |
| Transcriptional regulation by small RNAs | 47 | 4.32e-01 | -0.066200 | 6.33e-01 |
| Glycosaminoglycan metabolism | 69 | 3.43e-01 | 0.066100 | 5.44e-01 |
| RNA polymerase II transcribes snRNA genes | 68 | 3.48e-01 | -0.066000 | 5.48e-01 |
| Epigenetic regulation of gene expression | 116 | 2.22e-01 | 0.065800 | 4.04e-01 |
| Cellular responses to stimuli | 638 | 5.30e-03 | -0.065600 | 2.64e-02 |
| rRNA processing | 203 | 1.14e-01 | -0.064600 | 2.62e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 16 | 6.56e-01 | 0.064300 | 8.03e-01 |
| Processing of DNA double-strand break ends | 52 | 4.23e-01 | -0.064200 | 6.24e-01 |
| Post-translational protein modification | 994 | 9.32e-04 | -0.063500 | 6.35e-03 |
| RMTs methylate histone arginines | 30 | 5.48e-01 | 0.063400 | 7.35e-01 |
| MAPK family signaling cascades | 203 | 1.21e-01 | -0.063400 | 2.72e-01 |
| Diseases of mitotic cell cycle | 31 | 5.42e-01 | -0.063300 | 7.29e-01 |
| HDR through MMEJ (alt-NHEJ) | 11 | 7.18e-01 | 0.062900 | 8.50e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 76 | 3.46e-01 | -0.062700 | 5.46e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 17 | 6.56e-01 | -0.062400 | 8.03e-01 |
| Platelet calcium homeostasis | 15 | 6.76e-01 | 0.062300 | 8.14e-01 |
| G beta:gamma signalling through PI3Kgamma | 18 | 6.48e-01 | 0.062300 | 8.01e-01 |
| The NLRP3 inflammasome | 15 | 6.79e-01 | 0.061700 | 8.16e-01 |
| RUNX2 regulates osteoblast differentiation | 12 | 7.12e-01 | 0.061700 | 8.45e-01 |
| RHO GTPases Activate ROCKs | 17 | 6.61e-01 | -0.061400 | 8.07e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 256 | 9.26e-02 | -0.061400 | 2.21e-01 |
| Developmental Biology | 597 | 1.20e-02 | 0.061000 | 4.88e-02 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 39 | 5.11e-01 | 0.060800 | 7.05e-01 |
| AURKA Activation by TPX2 | 60 | 4.16e-01 | 0.060800 | 6.18e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 31 | 5.60e-01 | 0.060500 | 7.44e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 4.56e-01 | 0.060300 | 6.58e-01 |
| TRAF6 mediated NF-kB activation | 20 | 6.42e-01 | 0.060100 | 8.00e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 29 | 5.76e-01 | 0.060000 | 7.52e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 29 | 5.76e-01 | 0.060000 | 7.52e-01 |
| Downregulation of ERBB2 signaling | 18 | 6.60e-01 | 0.059900 | 8.06e-01 |
| Homology Directed Repair | 81 | 3.53e-01 | -0.059800 | 5.52e-01 |
| Transport of small molecules | 399 | 4.24e-02 | -0.059800 | 1.31e-01 |
| Negative regulation of FGFR1 signaling | 19 | 6.53e-01 | 0.059600 | 8.03e-01 |
| Defective Intrinsic Pathway for Apoptosis | 20 | 6.48e-01 | -0.059100 | 8.01e-01 |
| ESR-mediated signaling | 126 | 2.57e-01 | 0.058600 | 4.49e-01 |
| Early SARS-CoV-2 Infection Events | 29 | 5.86e-01 | 0.058500 | 7.58e-01 |
| Spry regulation of FGF signaling | 16 | 6.86e-01 | -0.058400 | 8.21e-01 |
| B-WICH complex positively regulates rRNA expression | 25 | 6.14e-01 | -0.058400 | 7.76e-01 |
| Translation of Structural Proteins 9683701 | 29 | 5.88e-01 | 0.058100 | 7.58e-01 |
| Transport of vitamins, nucleosides, and related molecules | 26 | 6.15e-01 | 0.057000 | 7.77e-01 |
| SUMOylation of RNA binding proteins | 44 | 5.14e-01 | 0.057000 | 7.06e-01 |
| Synthesis of PA | 24 | 6.30e-01 | -0.056900 | 7.91e-01 |
| Vesicle-mediated transport | 518 | 2.89e-02 | -0.056800 | 9.63e-02 |
| Protein-protein interactions at synapses | 33 | 5.76e-01 | 0.056200 | 7.52e-01 |
| Membrane Trafficking | 500 | 3.33e-02 | -0.056200 | 1.08e-01 |
| Plasma lipoprotein clearance | 29 | 6.04e-01 | -0.055700 | 7.68e-01 |
| Bile acid and bile salt metabolism | 19 | 6.75e-01 | 0.055600 | 8.14e-01 |
| Synthesis of PC | 19 | 6.77e-01 | 0.055300 | 8.14e-01 |
| Glycogen metabolism | 20 | 6.70e-01 | -0.055100 | 8.11e-01 |
| ADP signalling through P2Y purinoceptor 12 | 12 | 7.43e-01 | -0.054800 | 8.67e-01 |
| Regulation of TNFR1 signaling | 44 | 5.31e-01 | 0.054600 | 7.21e-01 |
| Biotin transport and metabolism | 11 | 7.54e-01 | -0.054500 | 8.72e-01 |
| PIP3 activates AKT signaling | 201 | 1.86e-01 | -0.054300 | 3.63e-01 |
| Processing of Intronless Pre-mRNAs | 20 | 6.74e-01 | 0.054300 | 8.14e-01 |
| Carboxyterminal post-translational modifications of tubulin | 22 | 6.63e-01 | -0.053800 | 8.08e-01 |
| Suppression of phagosomal maturation | 12 | 7.49e-01 | -0.053300 | 8.69e-01 |
| Sema4D induced cell migration and growth-cone collapse | 15 | 7.21e-01 | 0.053300 | 8.53e-01 |
| Post NMDA receptor activation events | 47 | 5.28e-01 | 0.053200 | 7.19e-01 |
| Transmission across Chemical Synapses | 108 | 3.42e-01 | 0.053100 | 5.44e-01 |
| DNA Double Strand Break Response | 40 | 5.63e-01 | 0.053000 | 7.44e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 40 | 5.63e-01 | -0.052900 | 7.44e-01 |
| CD28 co-stimulation | 28 | 6.30e-01 | 0.052700 | 7.91e-01 |
| Neutrophil degranulation | 381 | 8.04e-02 | -0.052600 | 2.04e-01 |
| mRNA 3’-end processing | 55 | 5.01e-01 | -0.052600 | 6.95e-01 |
| Anchoring of the basal body to the plasma membrane | 83 | 4.12e-01 | 0.052200 | 6.14e-01 |
| Signaling by ERBB2 ECD mutants | 12 | 7.56e-01 | 0.051900 | 8.73e-01 |
| TNFR1-induced proapoptotic signaling | 23 | 6.69e-01 | 0.051500 | 8.11e-01 |
| HDR through Homologous Recombination (HRR) | 51 | 5.26e-01 | -0.051400 | 7.18e-01 |
| Activation of GABAB receptors | 17 | 7.14e-01 | -0.051300 | 8.46e-01 |
| GABA B receptor activation | 17 | 7.14e-01 | -0.051300 | 8.46e-01 |
| Collagen degradation | 21 | 6.85e-01 | 0.051200 | 8.20e-01 |
| Diseases of DNA repair | 41 | 5.72e-01 | -0.051100 | 7.52e-01 |
| Translesion synthesis by POLI | 16 | 7.25e-01 | -0.050900 | 8.56e-01 |
| Cyclin D associated events in G1 | 39 | 5.83e-01 | 0.050900 | 7.56e-01 |
| G1 Phase | 39 | 5.83e-01 | 0.050900 | 7.56e-01 |
| Nicotinate metabolism | 22 | 6.81e-01 | 0.050600 | 8.18e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 41 | 5.75e-01 | -0.050600 | 7.52e-01 |
| Platelet sensitization by LDL | 14 | 7.46e-01 | 0.050100 | 8.68e-01 |
| SARS-CoV Infections | 345 | 1.13e-01 | 0.050000 | 2.62e-01 |
| Activation of NMDA receptors and postsynaptic events | 54 | 5.28e-01 | 0.049800 | 7.19e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 60 | 5.07e-01 | 0.049600 | 7.01e-01 |
| Reproduction | 46 | 5.62e-01 | 0.049400 | 7.44e-01 |
| Tie2 Signaling | 13 | 7.65e-01 | -0.047900 | 8.77e-01 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 33 | 6.35e-01 | -0.047800 | 7.94e-01 |
| Diseases of DNA Double-Strand Break Repair | 33 | 6.35e-01 | -0.047800 | 7.94e-01 |
| Cytochrome c-mediated apoptotic response | 12 | 7.75e-01 | 0.047800 | 8.81e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 17 | 7.34e-01 | -0.047500 | 8.61e-01 |
| Trafficking of AMPA receptors | 17 | 7.34e-01 | -0.047500 | 8.61e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 32 | 6.43e-01 | -0.047400 | 8.01e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 44 | 5.87e-01 | 0.047300 | 7.58e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 326 | 1.47e-01 | 0.047000 | 3.08e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 32 | 6.46e-01 | 0.046900 | 8.01e-01 |
| Nuclear Envelope Breakdown | 48 | 5.75e-01 | 0.046800 | 7.52e-01 |
| ISG15 antiviral mechanism | 71 | 4.99e-01 | 0.046500 | 6.95e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 7.73e-01 | -0.046300 | 8.81e-01 |
| Signaling by FGFR | 56 | 5.53e-01 | -0.045900 | 7.38e-01 |
| L1CAM interactions | 63 | 5.30e-01 | -0.045800 | 7.21e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 17 | 7.48e-01 | 0.045100 | 8.69e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 10 | 8.09e-01 | 0.044100 | 8.99e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 10 | 8.09e-01 | 0.044100 | 8.99e-01 |
| Peptide hormone metabolism | 35 | 6.52e-01 | 0.044100 | 8.03e-01 |
| Downstream signaling of activated FGFR2 | 11 | 8.00e-01 | 0.044100 | 8.95e-01 |
| Downstream signaling of activated FGFR3 | 11 | 8.00e-01 | 0.044100 | 8.95e-01 |
| Downstream signaling of activated FGFR4 | 11 | 8.00e-01 | 0.044100 | 8.95e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 17 | 7.54e-01 | -0.043900 | 8.72e-01 |
| Neurodegenerative Diseases | 17 | 7.54e-01 | -0.043900 | 8.72e-01 |
| Signaling by ERBB2 | 35 | 6.55e-01 | 0.043600 | 8.03e-01 |
| Vitamin B5 (pantothenate) metabolism | 13 | 7.86e-01 | -0.043600 | 8.89e-01 |
| Constitutive Signaling by EGFRvIII | 12 | 7.94e-01 | 0.043600 | 8.94e-01 |
| Signaling by EGFRvIII in Cancer | 12 | 7.94e-01 | 0.043600 | 8.94e-01 |
| Extra-nuclear estrogen signaling | 51 | 5.93e-01 | 0.043300 | 7.63e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 69 | 5.36e-01 | -0.043200 | 7.26e-01 |
| HCMV Infection | 88 | 4.86e-01 | -0.043100 | 6.83e-01 |
| Activation of HOX genes during differentiation | 45 | 6.18e-01 | 0.043100 | 7.79e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 45 | 6.18e-01 | 0.043100 | 7.79e-01 |
| Transport of Mature Transcript to Cytoplasm | 78 | 5.12e-01 | -0.043000 | 7.05e-01 |
| Molecules associated with elastic fibres | 12 | 7.97e-01 | 0.042900 | 8.95e-01 |
| Protein ubiquitination | 60 | 5.68e-01 | -0.042700 | 7.49e-01 |
| Late endosomal microautophagy | 30 | 6.87e-01 | -0.042600 | 8.21e-01 |
| Organelle biogenesis and maintenance | 237 | 2.63e-01 | -0.042400 | 4.55e-01 |
| HDR through Single Strand Annealing (SSA) | 30 | 6.91e-01 | -0.042000 | 8.24e-01 |
| Regulation of TP53 Activity through Phosphorylation | 73 | 5.38e-01 | -0.041700 | 7.27e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 66 | 5.61e-01 | -0.041500 | 7.44e-01 |
| Amplification of signal from the kinetochores | 66 | 5.61e-01 | -0.041500 | 7.44e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 22 | 7.38e-01 | 0.041300 | 8.63e-01 |
| Transcriptional Regulation by E2F6 | 30 | 6.96e-01 | 0.041200 | 8.29e-01 |
| Neuronal System | 141 | 4.00e-01 | 0.041200 | 6.01e-01 |
| Negative regulation of MAPK pathway | 37 | 6.71e-01 | 0.040400 | 8.11e-01 |
| The phototransduction cascade | 18 | 7.67e-01 | -0.040300 | 8.77e-01 |
| Peroxisomal protein import | 54 | 6.09e-01 | -0.040300 | 7.72e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 45 | 6.45e-01 | 0.039800 | 8.01e-01 |
| Regulation of TP53 Activity | 135 | 4.28e-01 | 0.039600 | 6.28e-01 |
| Viral Infection Pathways | 617 | 9.81e-02 | -0.039600 | 2.32e-01 |
| Nonhomologous End-Joining (NHEJ) | 31 | 7.05e-01 | 0.039300 | 8.39e-01 |
| ECM proteoglycans | 18 | 7.75e-01 | 0.039000 | 8.81e-01 |
| Integrin cell surface interactions | 35 | 6.91e-01 | 0.038900 | 8.24e-01 |
| G beta:gamma signalling through PLC beta | 12 | 8.16e-01 | -0.038700 | 9.00e-01 |
| Presynaptic function of Kainate receptors | 12 | 8.16e-01 | -0.038700 | 9.00e-01 |
| Signal transduction by L1 | 16 | 7.90e-01 | -0.038600 | 8.92e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 13 | 8.10e-01 | 0.038500 | 8.99e-01 |
| Keratan sulfate/keratin metabolism | 19 | 7.72e-01 | 0.038400 | 8.81e-01 |
| Regulation of BACH1 activity | 11 | 8.26e-01 | -0.038300 | 9.07e-01 |
| SARS-CoV-2-host interactions | 169 | 3.94e-01 | 0.038200 | 5.98e-01 |
| activated TAK1 mediates p38 MAPK activation | 21 | 7.63e-01 | -0.038100 | 8.76e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 11 | 8.28e-01 | 0.037800 | 9.08e-01 |
| TNFs bind their physiological receptors | 11 | 8.28e-01 | -0.037800 | 9.08e-01 |
| Signaling by Retinoic Acid | 25 | 7.44e-01 | -0.037700 | 8.68e-01 |
| HCMV Late Events | 53 | 6.38e-01 | -0.037400 | 7.97e-01 |
| Translesion synthesis by POLK | 16 | 7.97e-01 | -0.037200 | 8.95e-01 |
| Cell recruitment (pro-inflammatory response) | 22 | 7.63e-01 | -0.037100 | 8.76e-01 |
| Purinergic signaling in leishmaniasis infection | 22 | 7.63e-01 | -0.037100 | 8.76e-01 |
| Signaling by ERBB2 in Cancer | 14 | 8.10e-01 | 0.037100 | 8.99e-01 |
| Signalling to ERKs | 27 | 7.39e-01 | 0.037000 | 8.64e-01 |
| E2F mediated regulation of DNA replication | 18 | 7.90e-01 | -0.036300 | 8.92e-01 |
| Membrane binding and targetting of GAG proteins | 14 | 8.15e-01 | -0.036100 | 9.00e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 8.15e-01 | -0.036100 | 9.00e-01 |
| EML4 and NUDC in mitotic spindle formation | 79 | 5.82e-01 | -0.035800 | 7.56e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 18 | 7.93e-01 | -0.035700 | 8.94e-01 |
| Extracellular matrix organization | 107 | 5.25e-01 | 0.035600 | 7.18e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 17 | 8.01e-01 | 0.035400 | 8.95e-01 |
| CRMPs in Sema3A signaling | 12 | 8.32e-01 | 0.035300 | 9.10e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 28 | 7.48e-01 | 0.035000 | 8.69e-01 |
| RHO GTPases Activate WASPs and WAVEs | 34 | 7.24e-01 | -0.035000 | 8.56e-01 |
| Glycosphingolipid catabolism | 24 | 7.70e-01 | 0.034500 | 8.80e-01 |
| SUMOylation of chromatin organization proteins | 53 | 6.70e-01 | 0.033900 | 8.11e-01 |
| Positive epigenetic regulation of rRNA expression | 40 | 7.14e-01 | -0.033600 | 8.46e-01 |
| RHO GTPase Effectors | 197 | 4.20e-01 | -0.033500 | 6.22e-01 |
| Signaling by high-kinase activity BRAF mutants | 29 | 7.56e-01 | -0.033400 | 8.73e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 10 | 8.55e-01 | -0.033300 | 9.26e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 37 | 7.28e-01 | -0.033100 | 8.56e-01 |
| Signaling by RAS mutants | 37 | 7.28e-01 | -0.033100 | 8.56e-01 |
| Signaling by moderate kinase activity BRAF mutants | 37 | 7.28e-01 | -0.033100 | 8.56e-01 |
| Signaling downstream of RAS mutants | 37 | 7.28e-01 | -0.033100 | 8.56e-01 |
| Assembly of collagen fibrils and other multimeric structures | 19 | 8.06e-01 | 0.032500 | 8.98e-01 |
| Maturation of spike protein 9694548 | 34 | 7.43e-01 | -0.032500 | 8.67e-01 |
| EPHA-mediated growth cone collapse | 11 | 8.54e-01 | -0.032000 | 9.26e-01 |
| Intracellular signaling by second messengers | 228 | 4.08e-01 | -0.032000 | 6.10e-01 |
| Cytosolic sensors of pathogen-associated DNA | 56 | 6.80e-01 | -0.032000 | 8.16e-01 |
| Ion channel transport | 90 | 6.02e-01 | -0.031900 | 7.67e-01 |
| Glucagon signaling in metabolic regulation | 19 | 8.11e-01 | -0.031700 | 8.99e-01 |
| SARS-CoV-2 Infection | 246 | 3.97e-01 | 0.031500 | 5.99e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 31 | 7.63e-01 | 0.031400 | 8.76e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 16 | 8.33e-01 | 0.030500 | 9.10e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 16 | 8.33e-01 | 0.030500 | 9.10e-01 |
| Thromboxane signalling through TP receptor | 15 | 8.39e-01 | -0.030200 | 9.13e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 41 | 7.38e-01 | 0.030200 | 8.63e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 14 | 8.48e-01 | -0.029700 | 9.19e-01 |
| Activation of kainate receptors upon glutamate binding | 15 | 8.45e-01 | -0.029200 | 9.17e-01 |
| SARS-CoV-1 activates/modulates innate immune responses | 36 | 7.64e-01 | -0.028900 | 8.77e-01 |
| Aquaporin-mediated transport | 24 | 8.11e-01 | -0.028200 | 8.99e-01 |
| TAK1-dependent IKK and NF-kappa-B activation | 39 | 7.66e-01 | 0.027600 | 8.77e-01 |
| Homologous DNA Pairing and Strand Exchange | 34 | 7.82e-01 | -0.027400 | 8.87e-01 |
| Ion transport by P-type ATPases | 30 | 8.01e-01 | -0.026600 | 8.95e-01 |
| Sensory processing of sound | 30 | 8.02e-01 | 0.026500 | 8.95e-01 |
| Arachidonic acid metabolism | 22 | 8.32e-01 | -0.026200 | 9.10e-01 |
| G alpha (z) signalling events | 25 | 8.22e-01 | -0.026000 | 9.04e-01 |
| SUMOylation of SUMOylation proteins | 34 | 7.95e-01 | 0.025800 | 8.95e-01 |
| Post-translational protein phosphorylation | 43 | 7.74e-01 | 0.025300 | 8.81e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 29 | 8.14e-01 | -0.025200 | 9.00e-01 |
| Regulation of innate immune responses to cytosolic DNA | 11 | 8.86e-01 | -0.025100 | 9.43e-01 |
| SUMOylation of transcription factors | 14 | 8.72e-01 | 0.024900 | 9.39e-01 |
| Glycosphingolipid metabolism | 31 | 8.11e-01 | -0.024800 | 8.99e-01 |
| MET promotes cell motility | 18 | 8.57e-01 | -0.024600 | 9.27e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 10 | 8.95e-01 | 0.024200 | 9.48e-01 |
| Sphingolipid de novo biosynthesis | 25 | 8.36e-01 | -0.023900 | 9.12e-01 |
| Generic Transcription Pathway | 863 | 2.57e-01 | 0.023200 | 4.49e-01 |
| Signaling by EGFR in Cancer | 17 | 8.70e-01 | -0.022900 | 9.37e-01 |
| Class A/1 (Rhodopsin-like receptors) | 56 | 7.67e-01 | 0.022900 | 8.77e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 81 | 7.28e-01 | 0.022400 | 8.56e-01 |
| Transport of the SLBP Dependant Mature mRNA | 35 | 8.23e-01 | -0.021900 | 9.05e-01 |
| Signaling by Interleukins | 313 | 5.10e-01 | -0.021800 | 7.04e-01 |
| Mitotic Prometaphase | 153 | 6.43e-01 | 0.021800 | 8.01e-01 |
| RIP-mediated NFkB activation via ZBP1 | 15 | 8.85e-01 | -0.021500 | 9.43e-01 |
| Immune System | 1386 | 1.95e-01 | 0.021500 | 3.76e-01 |
| Class I MHC mediated antigen processing & presentation | 322 | 5.12e-01 | -0.021400 | 7.05e-01 |
| Late SARS-CoV-2 Infection Events | 58 | 7.79e-01 | 0.021400 | 8.84e-01 |
| CTLA4 inhibitory signaling | 17 | 8.79e-01 | 0.021300 | 9.42e-01 |
| SARS-CoV-1-host interactions | 88 | 7.32e-01 | -0.021200 | 8.60e-01 |
| Centrosome maturation | 70 | 7.60e-01 | 0.021100 | 8.76e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 70 | 7.60e-01 | 0.021100 | 8.76e-01 |
| Signaling by RAF1 mutants | 33 | 8.36e-01 | -0.020800 | 9.12e-01 |
| Integration of energy metabolism | 59 | 7.83e-01 | -0.020800 | 8.87e-01 |
| Cytokine Signaling in Immune system | 541 | 4.15e-01 | 0.020700 | 6.18e-01 |
| Gene expression (Transcription) | 1115 | 2.59e-01 | 0.020600 | 4.50e-01 |
| Nuclear import of Rev protein | 33 | 8.39e-01 | 0.020500 | 9.13e-01 |
| TRP channels | 12 | 9.02e-01 | -0.020500 | 9.50e-01 |
| TGF-beta receptor signaling activates SMADs | 35 | 8.36e-01 | 0.020300 | 9.12e-01 |
| Integrin signaling | 22 | 8.70e-01 | -0.020200 | 9.37e-01 |
| Protein methylation | 14 | 8.97e-01 | -0.019900 | 9.49e-01 |
| EGFR downregulation | 20 | 8.79e-01 | -0.019700 | 9.42e-01 |
| Downregulation of TGF-beta receptor signaling | 24 | 8.68e-01 | 0.019700 | 9.36e-01 |
| Signaling by ERBB2 KD Mutants | 13 | 9.03e-01 | -0.019600 | 9.50e-01 |
| Diseases associated with O-glycosylation of proteins | 16 | 8.95e-01 | 0.019100 | 9.48e-01 |
| Negative regulation of FGFR2 signaling | 17 | 8.93e-01 | -0.018900 | 9.48e-01 |
| Negative regulation of FGFR3 signaling | 17 | 8.93e-01 | -0.018900 | 9.48e-01 |
| Negative regulation of FGFR4 signaling | 17 | 8.93e-01 | -0.018900 | 9.48e-01 |
| Platelet Aggregation (Plug Formation) | 23 | 8.76e-01 | 0.018800 | 9.41e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 9.15e-01 | 0.018600 | 9.55e-01 |
| HATs acetylate histones | 75 | 7.83e-01 | 0.018400 | 8.87e-01 |
| SUMOylation of DNA replication proteins | 39 | 8.43e-01 | 0.018300 | 9.16e-01 |
| Regulation of HSF1-mediated heat shock response | 70 | 7.97e-01 | -0.017800 | 8.95e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 87 | 7.76e-01 | 0.017700 | 8.82e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 23 | 8.85e-01 | 0.017500 | 9.43e-01 |
| NOD1/2 Signaling Pathway | 33 | 8.63e-01 | 0.017400 | 9.32e-01 |
| GABA receptor activation | 19 | 8.97e-01 | -0.017200 | 9.49e-01 |
| Signal regulatory protein family interactions | 11 | 9.22e-01 | -0.017100 | 9.59e-01 |
| Muscle contraction | 72 | 8.03e-01 | 0.017000 | 8.96e-01 |
| Signaling by FGFR3 | 25 | 8.85e-01 | 0.016700 | 9.43e-01 |
| Signaling by FGFR4 | 25 | 8.85e-01 | 0.016700 | 9.43e-01 |
| Sphingolipid metabolism | 63 | 8.19e-01 | 0.016700 | 9.01e-01 |
| RIPK1-mediated regulated necrosis | 29 | 8.77e-01 | -0.016700 | 9.41e-01 |
| Regulation of necroptotic cell death | 29 | 8.77e-01 | -0.016700 | 9.41e-01 |
| Purine salvage | 12 | 9.20e-01 | -0.016700 | 9.59e-01 |
| Antiviral mechanism by IFN-stimulated genes | 130 | 7.47e-01 | -0.016400 | 8.69e-01 |
| RNA Polymerase II Transcription | 976 | 3.97e-01 | 0.016400 | 5.99e-01 |
| SARS-CoV-1 Infection | 131 | 7.48e-01 | -0.016300 | 8.69e-01 |
| Hemostasis | 353 | 6.08e-01 | 0.016000 | 7.72e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 10 | 9.32e-01 | 0.015600 | 9.64e-01 |
| GPCR ligand binding | 76 | 8.17e-01 | 0.015300 | 9.01e-01 |
| Sensory processing of sound by outer hair cells of the cochlea | 23 | 8.99e-01 | 0.015200 | 9.50e-01 |
| Rev-mediated nuclear export of HIV RNA | 34 | 8.83e-01 | -0.014600 | 9.43e-01 |
| NF-kB is activated and signals survival | 11 | 9.33e-01 | 0.014600 | 9.65e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 20 | 9.12e-01 | -0.014300 | 9.55e-01 |
| Interleukin-10 signaling | 26 | 9.01e-01 | 0.014200 | 9.50e-01 |
| Infectious disease | 753 | 5.24e-01 | -0.013900 | 7.16e-01 |
| Rab regulation of trafficking | 113 | 8.02e-01 | -0.013700 | 8.96e-01 |
| Cytochrome P450 - arranged by substrate type | 18 | 9.22e-01 | 0.013300 | 9.59e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 48 | 8.74e-01 | -0.013200 | 9.40e-01 |
| Sialic acid metabolism | 23 | 9.13e-01 | 0.013200 | 9.55e-01 |
| Non-integrin membrane-ECM interactions | 23 | 9.15e-01 | -0.012900 | 9.55e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 20 | 9.23e-01 | -0.012500 | 9.59e-01 |
| Nucleosome assembly | 20 | 9.23e-01 | -0.012500 | 9.59e-01 |
| Diseases of programmed cell death | 40 | 8.95e-01 | -0.012100 | 9.48e-01 |
| Innate Immune System | 754 | 6.09e-01 | -0.011100 | 7.72e-01 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 42 | 9.02e-01 | 0.011000 | 9.50e-01 |
| Phase I - Functionalization of compounds | 39 | 9.07e-01 | -0.010800 | 9.53e-01 |
| Meiotic recombination | 17 | 9.41e-01 | 0.010400 | 9.69e-01 |
| Signal amplification | 21 | 9.35e-01 | -0.010300 | 9.66e-01 |
| Signaling by EGFR | 36 | 9.15e-01 | -0.010300 | 9.55e-01 |
| Signaling by Hippo | 15 | 9.46e-01 | 0.010100 | 9.71e-01 |
| G1/S-Specific Transcription | 15 | 9.48e-01 | -0.009810 | 9.72e-01 |
| Ion homeostasis | 27 | 9.31e-01 | 0.009700 | 9.64e-01 |
| Cell surface interactions at the vascular wall | 76 | 8.84e-01 | -0.009670 | 9.43e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 12 | 9.54e-01 | 0.009610 | 9.76e-01 |
| Assembly and cell surface presentation of NMDA receptors | 21 | 9.40e-01 | -0.009500 | 9.69e-01 |
| ER Quality Control Compartment (ERQC) | 20 | 9.44e-01 | -0.009150 | 9.71e-01 |
| Retrograde transport at the Trans-Golgi-Network | 48 | 9.13e-01 | -0.009100 | 9.55e-01 |
| Platelet homeostasis | 46 | 9.16e-01 | -0.009020 | 9.55e-01 |
| Recruitment of NuMA to mitotic centrosomes | 74 | 8.94e-01 | -0.008950 | 9.48e-01 |
| HCMV Early Events | 65 | 9.08e-01 | 0.008300 | 9.53e-01 |
| SUMOylation of ubiquitinylation proteins | 38 | 9.30e-01 | 0.008240 | 9.64e-01 |
| HSF1-dependent transactivation | 26 | 9.44e-01 | 0.007930 | 9.71e-01 |
| Disease | 1227 | 6.67e-01 | 0.007510 | 8.10e-01 |
| Meiosis | 35 | 9.40e-01 | 0.007330 | 9.69e-01 |
| Formation of apoptosome | 10 | 9.69e-01 | -0.007210 | 9.81e-01 |
| Regulation of the apoptosome activity | 10 | 9.69e-01 | -0.007210 | 9.81e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 14 | 9.63e-01 | -0.007090 | 9.79e-01 |
| Metal ion SLC transporters | 17 | 9.60e-01 | -0.006950 | 9.79e-01 |
| Interactions of Rev with host cellular proteins | 36 | 9.45e-01 | 0.006670 | 9.71e-01 |
| EPH-ephrin mediated repulsion of cells | 28 | 9.53e-01 | -0.006510 | 9.76e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 23 | 9.58e-01 | 0.006330 | 9.78e-01 |
| Gene Silencing by RNA | 67 | 9.29e-01 | -0.006270 | 9.64e-01 |
| Nervous system development | 372 | 8.40e-01 | -0.006150 | 9.13e-01 |
| Cellular response to starvation | 143 | 9.02e-01 | 0.006010 | 9.50e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 12 | 9.72e-01 | 0.005910 | 9.82e-01 |
| Class B/2 (Secretin family receptors) | 20 | 9.64e-01 | -0.005820 | 9.79e-01 |
| Cellular response to heat stress | 85 | 9.26e-01 | 0.005820 | 9.61e-01 |
| Netrin-1 signaling | 21 | 9.63e-01 | 0.005800 | 9.79e-01 |
| Axon guidance | 360 | 8.61e-01 | -0.005400 | 9.31e-01 |
| GPER1 signaling | 29 | 9.60e-01 | -0.005340 | 9.79e-01 |
| Platelet activation, signaling and aggregation | 169 | 9.06e-01 | 0.005260 | 9.53e-01 |
| Attenuation phase | 19 | 9.69e-01 | -0.005200 | 9.81e-01 |
| Meiotic synapsis | 20 | 9.68e-01 | -0.005170 | 9.81e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 28 | 9.63e-01 | 0.005120 | 9.79e-01 |
| Cilium Assembly | 155 | 9.14e-01 | -0.005040 | 9.55e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 18 | 9.74e-01 | 0.004500 | 9.83e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 22 | 9.72e-01 | 0.004360 | 9.82e-01 |
| Regulation of PTEN gene transcription | 54 | 9.61e-01 | -0.003860 | 9.79e-01 |
| Mitotic Prophase | 77 | 9.54e-01 | 0.003800 | 9.76e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 12 | 9.83e-01 | 0.003630 | 9.91e-01 |
| Resolution of Sister Chromatid Cohesion | 86 | 9.55e-01 | -0.003510 | 9.76e-01 |
| SARS-CoV-2 modulates autophagy | 11 | 9.84e-01 | -0.003470 | 9.92e-01 |
| DNA Double-Strand Break Repair | 106 | 9.55e-01 | 0.003190 | 9.76e-01 |
| Cargo trafficking to the periciliary membrane | 39 | 9.74e-01 | -0.003060 | 9.83e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 9.88e-01 | -0.002430 | 9.94e-01 |
| Metabolism of lipids | 499 | 9.38e-01 | -0.002040 | 9.69e-01 |
| Other interleukin signaling | 16 | 9.90e-01 | -0.001840 | 9.94e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 18 | 9.89e-01 | 0.001830 | 9.94e-01 |
| Translation of Structural Proteins 9694635 | 54 | 9.87e-01 | -0.001320 | 9.93e-01 |
| Syndecan interactions | 15 | 9.97e-01 | -0.000552 | 9.98e-01 |
| Defects in vitamin and cofactor metabolism | 17 | 9.97e-01 | 0.000455 | 9.98e-01 |
| Transport of the SLBP independent Mature mRNA | 34 | 9.97e-01 | 0.000355 | 9.98e-01 |
| MHC class II antigen presentation | 93 | 9.97e-01 | 0.000263 | 9.98e-01 |
| Adaptive Immune System | 570 | 9.95e-01 | -0.000159 | 9.98e-01 |
| Response of Mtb to phagocytosis | 21 | 1.00e+00 | -0.000060 | 1.00e+00 |
Detailed Gene set reports
APOBEC3G mediated resistance to HIV-1 infection
| 18 | |
|---|---|
| set | APOBEC3G mediated resistance to HIV-1 infection |
| setSize | 10 |
| pANOVA | 2.65e-05 |
| s.dist | -0.767 |
| p.adjustANOVA | 0.000263 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| HMGA1 | -3736.5 |
| rev | -3664.5 |
| BANF1 | -3254.5 |
| PPIA | -2464.5 |
| APOBEC3G | -550.5 |
| PSIP1 | 2964.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| HMGA1 | -3736.5 |
| rev | -3664.5 |
| BANF1 | -3254.5 |
| PPIA | -2464.5 |
| APOBEC3G | -550.5 |
| PSIP1 | 2964.5 |
Mitochondrial translation termination
| 624 | |
|---|---|
| set | Mitochondrial translation termination |
| setSize | 88 |
| pANOVA | 2.26e-27 |
| s.dist | -0.668 |
| p.adjustANOVA | 1.11e-24 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
| CHCHD1 | -3426.5 |
| MRPS17 | -3379.5 |
| MRPL55 | -3374.5 |
| MRPL27 | -3370.5 |
| MRPL14 | -3366.5 |
| MRPL21 | -3315.5 |
| MRPL28 | -3303.5 |
| MRPS26 | -3301.5 |
| MRPL51 | -3299.5 |
| MRPS22 | -3256.5 |
| MRPL40 | -3210.5 |
| MRPL18 | -3183.5 |
| MRPL22 | -3170.5 |
| MRPL23 | -3168.5 |
| MRPL39 | -3131.5 |
| MRPL11 | -3094.5 |
| MRPL12 | -3068.5 |
| MRPL36 | -3063.5 |
| GADD45GIP1 | -3036.5 |
| MRPL24 | -2997.5 |
| MRPS18A | -2932.5 |
| MRPS10 | -2929.5 |
| MRPL47 | -2896.5 |
| MRPL20 | -2722.5 |
| MRPL2 | -2689.5 |
| MRPL50 | -2640.5 |
| MRPS11 | -2627.5 |
| MRPL48 | -2626.5 |
| MTRF1L | -2589.5 |
| MRPS23 | -2537.5 |
| MRPL43 | -2491.5 |
| MRPS2 | -2474.5 |
| MRPL19 | -2402.5 |
| MRPS28 | -2216.5 |
| MRPL17 | -2190.5 |
| MRPL16 | -2017.5 |
| ERAL1 | -1888.5 |
| MRPL3 | -1886.5 |
| MRPL13 | -1841.5 |
| MRPS35 | -1825.5 |
| MRPL30 | -1665.5 |
| MRPL4 | -1563.5 |
| MRRF | -1546.5 |
| MRPL38 | -1493.5 |
| MRPL10 | -1425.5 |
| MRPS5 | -1190.5 |
| DAP3 | -1168.5 |
| MRPL15 | -801.5 |
| MRPL32 | -790.5 |
| MRPS14 | -772.5 |
| MRPL44 | -647.5 |
| MRPL45 | -503.5 |
| MRPS18B | -502.5 |
| MRPL53 | -457.5 |
| MRPL58 | -393.5 |
| MRPS30 | -352.5 |
| MRPS21 | -81.5 |
| MRPL46 | -77.5 |
| MRPL37 | 39.5 |
| MRPL49 | 504.5 |
| MRPS31 | 525.5 |
| GFM2 | 677.5 |
| MRPS9 | 1076.5 |
| MRPS27 | 1982.5 |
| MRPL9 | 2234.5 |
| PTCD3 | 2566.5 |
| MRPL1 | 3380.5 |
| OXA1L | 6780.5 |
Mitochondrial translation elongation
| 622 | |
|---|---|
| set | Mitochondrial translation elongation |
| setSize | 88 |
| pANOVA | 2.54e-27 |
| s.dist | -0.667 |
| p.adjustANOVA | 1.11e-24 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
| CHCHD1 | -3426.5 |
| MRPS17 | -3379.5 |
| MRPL55 | -3374.5 |
| MRPL27 | -3370.5 |
| MRPL14 | -3366.5 |
| MRPL21 | -3315.5 |
| MRPL28 | -3303.5 |
| MRPS26 | -3301.5 |
| MRPL51 | -3299.5 |
| MRPS22 | -3256.5 |
| MRPL40 | -3210.5 |
| MRPL18 | -3183.5 |
| MRPL22 | -3170.5 |
| MRPL23 | -3168.5 |
| MRPL39 | -3131.5 |
| MRPL11 | -3094.5 |
| MRPL12 | -3068.5 |
| MRPL36 | -3063.5 |
| GADD45GIP1 | -3036.5 |
| MRPL24 | -2997.5 |
| MRPS18A | -2932.5 |
| MRPS10 | -2929.5 |
| MRPL47 | -2896.5 |
| MRPL20 | -2722.5 |
| MRPL2 | -2689.5 |
| MRPL50 | -2640.5 |
| MRPS11 | -2627.5 |
| MRPL48 | -2626.5 |
| MRPS23 | -2537.5 |
| MRPL43 | -2491.5 |
| MRPS2 | -2474.5 |
| MRPL19 | -2402.5 |
| MRPS28 | -2216.5 |
| MRPL17 | -2190.5 |
| MRPL16 | -2017.5 |
| TUFM | -1895.5 |
| ERAL1 | -1888.5 |
| MRPL3 | -1886.5 |
| MRPL13 | -1841.5 |
| MRPS35 | -1825.5 |
| MRPL30 | -1665.5 |
| MRPL4 | -1563.5 |
| MRPL38 | -1493.5 |
| MRPL10 | -1425.5 |
| MRPS5 | -1190.5 |
| DAP3 | -1168.5 |
| MRPL15 | -801.5 |
| MRPL32 | -790.5 |
| MRPS14 | -772.5 |
| TSFM | -735.5 |
| MRPL44 | -647.5 |
| GFM1 | -510.5 |
| MRPL45 | -503.5 |
| MRPS18B | -502.5 |
| MRPL53 | -457.5 |
| MRPL58 | -393.5 |
| MRPS30 | -352.5 |
| MRPS21 | -81.5 |
| MRPL46 | -77.5 |
| MRPL37 | 39.5 |
| MRPL49 | 504.5 |
| MRPS31 | 525.5 |
| MRPS9 | 1076.5 |
| MRPS27 | 1982.5 |
| MRPL9 | 2234.5 |
| PTCD3 | 2566.5 |
| MRPL1 | 3380.5 |
| OXA1L | 6780.5 |
Mitochondrial translation initiation
| 623 | |
|---|---|
| set | Mitochondrial translation initiation |
| setSize | 88 |
| pANOVA | 3.6e-27 |
| s.dist | -0.665 |
| p.adjustANOVA | 1.18e-24 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
| CHCHD1 | -3426.5 |
| MRPS17 | -3379.5 |
| MRPL55 | -3374.5 |
| MRPL27 | -3370.5 |
| MRPL14 | -3366.5 |
| MRPL21 | -3315.5 |
| MRPL28 | -3303.5 |
| MRPS26 | -3301.5 |
| MRPL51 | -3299.5 |
| MRPS22 | -3256.5 |
| MRPL40 | -3210.5 |
| MRPL18 | -3183.5 |
| MRPL22 | -3170.5 |
| MRPL23 | -3168.5 |
| MRPL39 | -3131.5 |
| MRPL11 | -3094.5 |
| MRPL12 | -3068.5 |
| MRPL36 | -3063.5 |
| GADD45GIP1 | -3036.5 |
| MRPL24 | -2997.5 |
| MRPS18A | -2932.5 |
| MRPS10 | -2929.5 |
| MRPL47 | -2896.5 |
| MRPL20 | -2722.5 |
| MRPL2 | -2689.5 |
| MRPL50 | -2640.5 |
| MRPS11 | -2627.5 |
| MRPL48 | -2626.5 |
| MRPS23 | -2537.5 |
| MRPL43 | -2491.5 |
| MRPS2 | -2474.5 |
| MRPL19 | -2402.5 |
| MRPS28 | -2216.5 |
| MRPL17 | -2190.5 |
| MRPL16 | -2017.5 |
| ERAL1 | -1888.5 |
| MRPL3 | -1886.5 |
| MRPL13 | -1841.5 |
| MRPS35 | -1825.5 |
| MRPL30 | -1665.5 |
| MRPL4 | -1563.5 |
| MRPL38 | -1493.5 |
| MRPL10 | -1425.5 |
| MTIF3 | -1345.5 |
| MRPS5 | -1190.5 |
| DAP3 | -1168.5 |
| MRPL15 | -801.5 |
| MRPL32 | -790.5 |
| MRPS14 | -772.5 |
| MRPL44 | -647.5 |
| MTFMT | -620.5 |
| MRPL45 | -503.5 |
| MRPS18B | -502.5 |
| MRPL53 | -457.5 |
| MRPL58 | -393.5 |
| MRPS30 | -352.5 |
| MTIF2 | -218.5 |
| MRPS21 | -81.5 |
| MRPL46 | -77.5 |
| MRPL37 | 39.5 |
| MRPL49 | 504.5 |
| MRPS31 | 525.5 |
| MRPS9 | 1076.5 |
| MRPS27 | 1982.5 |
| MRPL9 | 2234.5 |
| PTCD3 | 2566.5 |
| MRPL1 | 3380.5 |
| OXA1L | 6780.5 |
Mitochondrial translation
| 621 | |
|---|---|
| set | Mitochondrial translation |
| setSize | 94 |
| pANOVA | 4.94e-28 |
| s.dist | -0.655 |
| p.adjustANOVA | 6.46e-25 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS6 | -3886.5 |
| MRPS16 | -3872.5 |
| MRPL41 | -3851.5 |
| MRPL52 | -3843.5 |
| MRPS34 | -3787.5 |
| MRPL33 | -3768.5 |
| AURKAIP1 | -3742.5 |
| MRPL54 | -3729.5 |
| MRPS33 | -3682.5 |
| MRPS24 | -3679.5 |
| MRPS15 | -3663.5 |
| MRPL57 | -3621.5 |
| MRPS36 | -3613.5 |
| MRPS7 | -3586.5 |
| MRPL35 | -3547.5 |
| MRPL34 | -3534.5 |
| MRPS25 | -3520.5 |
| MRPS18C | -3519.5 |
| MRPS12 | -3492.5 |
| MRPL42 | -3461.5 |
| CHCHD1 | -3426.5 |
| MRPS17 | -3379.5 |
| MRPL55 | -3374.5 |
| MRPL27 | -3370.5 |
| MRPL14 | -3366.5 |
| MRPL21 | -3315.5 |
| MRPL28 | -3303.5 |
| MRPS26 | -3301.5 |
| MRPL51 | -3299.5 |
| MRPS22 | -3256.5 |
| MRPL40 | -3210.5 |
| MRPL18 | -3183.5 |
| MRPL22 | -3170.5 |
| MRPL23 | -3168.5 |
| MRPL39 | -3131.5 |
| MRPL11 | -3094.5 |
| MRPL12 | -3068.5 |
| MRPL36 | -3063.5 |
| GADD45GIP1 | -3036.5 |
| MRPL24 | -2997.5 |
| MRPS18A | -2932.5 |
| MRPS10 | -2929.5 |
| MRPL47 | -2896.5 |
| MRPL20 | -2722.5 |
| MRPL2 | -2689.5 |
| MRPL50 | -2640.5 |
| MRPS11 | -2627.5 |
| MRPL48 | -2626.5 |
| MTRF1L | -2589.5 |
| MRPS23 | -2537.5 |
| MRPL43 | -2491.5 |
| MRPS2 | -2474.5 |
| MRPL19 | -2402.5 |
| MRPS28 | -2216.5 |
| MRPL17 | -2190.5 |
| MRPL16 | -2017.5 |
| TUFM | -1895.5 |
| ERAL1 | -1888.5 |
| MRPL3 | -1886.5 |
| MRPL13 | -1841.5 |
| MRPS35 | -1825.5 |
| MRPL30 | -1665.5 |
| MRPL4 | -1563.5 |
| MRRF | -1546.5 |
| MRPL38 | -1493.5 |
| MRPL10 | -1425.5 |
| MTIF3 | -1345.5 |
| MRPS5 | -1190.5 |
| DAP3 | -1168.5 |
| MRPL15 | -801.5 |
| MRPL32 | -790.5 |
| MRPS14 | -772.5 |
| TSFM | -735.5 |
| MRPL44 | -647.5 |
| MTFMT | -620.5 |
| GFM1 | -510.5 |
| MRPL45 | -503.5 |
| MRPS18B | -502.5 |
| MRPL53 | -457.5 |
| MRPL58 | -393.5 |
| MRPS30 | -352.5 |
| MTIF2 | -218.5 |
| MRPS21 | -81.5 |
| MRPL46 | -77.5 |
| MRPL37 | 39.5 |
| MRPL49 | 504.5 |
| MRPS31 | 525.5 |
| GFM2 | 677.5 |
| MRPS9 | 1076.5 |
| MRPS27 | 1982.5 |
| MRPL9 | 2234.5 |
| PTCD3 | 2566.5 |
| MRPL1 | 3380.5 |
| OXA1L | 6780.5 |
Metabolism of polyamines
| 599 | |
|---|---|
| set | Metabolism of polyamines |
| setSize | 54 |
| pANOVA | 3.71e-16 |
| s.dist | -0.641 |
| p.adjustANOVA | 5.56e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| SMS | -3859.5 |
| PSMA7 | -3842.5 |
| SRM | -3818.5 |
| OAZ1 | -3766.5 |
| SAT1 | -3762.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| SMS | -3859.5 |
| PSMA7 | -3842.5 |
| SRM | -3818.5 |
| OAZ1 | -3766.5 |
| SAT1 | -3762.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| AMD1 | -2839.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| NQO1 | -2428.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| OAZ3 | -890.5 |
| ODC1 | -556.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| AZIN1 | 90.5 |
| PSME2 | 135.5 |
| PAOX | 1385.5 |
| OAZ2 | 1416.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
| 316 | |
|---|---|
| set | Erythropoietin activates Phosphoinositide-3-kinase (PI3K) |
| setSize | 11 |
| pANOVA | 0.000243 |
| s.dist | 0.639 |
| p.adjustANOVA | 0.00197 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 6946.5 |
| JAK2 | 6926.5 |
| IRS2 | 6912.5 |
| PIK3CG | 6862.5 |
| PIK3CD | 6589.5 |
| PIK3R5 | 6361.5 |
| PIK3CA | 5474.5 |
| GAB1 | 5170.5 |
| PIK3R1 | 3829.5 |
| LYN | 2643.5 |
| EPOR | -834.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 6946.5 |
| JAK2 | 6926.5 |
| IRS2 | 6912.5 |
| PIK3CG | 6862.5 |
| PIK3CD | 6589.5 |
| PIK3R5 | 6361.5 |
| PIK3CA | 5474.5 |
| GAB1 | 5170.5 |
| PIK3R1 | 3829.5 |
| LYN | 2643.5 |
| EPOR | -834.5 |
Regulation of ornithine decarboxylase (ODC)
| 946 | |
|---|---|
| set | Regulation of ornithine decarboxylase (ODC) |
| setSize | 49 |
| pANOVA | 2.67e-14 |
| s.dist | -0.629 |
| p.adjustANOVA | 3.18e-12 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| OAZ1 | -3766.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| OAZ1 | -3766.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| NQO1 | -2428.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| OAZ3 | -890.5 |
| ODC1 | -556.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| AZIN1 | 90.5 |
| PSME2 | 135.5 |
| OAZ2 | 1416.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
Binding and entry of HIV virion
| 98 | |
|---|---|
| set | Binding and entry of HIV virion |
| setSize | 11 |
| pANOVA | 0.000455 |
| s.dist | -0.61 |
| p.adjustANOVA | 0.00346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| nef | -3943.5 |
| env | -3942.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| rev | -3664.5 |
| PPIA | -2464.5 |
| CXCR4 | 1988.5 |
| CCR5 | 2227.5 |
| CD4 | 6034.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| nef | -3943.5 |
| env | -3942.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| rev | -3664.5 |
| PPIA | -2464.5 |
| CXCR4 | 1988.5 |
| CCR5 | 2227.5 |
| CD4 | 6034.5 |
Folding of actin by CCT/TriC
| 349 | |
|---|---|
| set | Folding of actin by CCT/TriC |
| setSize | 10 |
| pANOVA | 0.000941 |
| s.dist | -0.604 |
| p.adjustANOVA | 0.00638 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ACTB | -3913.5 |
| CCT7 | -3362.5 |
| TCP1 | -3176.5 |
| CCT2 | -3104.5 |
| CCT5 | -2684.5 |
| CCT4 | -2582.5 |
| CCT3 | -1939.5 |
| CCT8 | -1808.5 |
| CCT6A | 2282.5 |
| CCT6B | 2902.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ACTB | -3913.5 |
| CCT7 | -3362.5 |
| TCP1 | -3176.5 |
| CCT2 | -3104.5 |
| CCT5 | -2684.5 |
| CCT4 | -2582.5 |
| CCT3 | -1939.5 |
| CCT8 | -1808.5 |
| CCT6A | 2282.5 |
| CCT6B | 2902.5 |
Vif-mediated degradation of APOBEC3G
| 1264 | |
|---|---|
| set | Vif-mediated degradation of APOBEC3G |
| setSize | 53 |
| pANOVA | 9.31e-14 |
| s.dist | -0.592 |
| p.adjustANOVA | 9.92e-12 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| vif | -3939.5 |
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| ELOC | -3840.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| vif | -3939.5 |
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| ELOC | -3840.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| ELOB | -2805.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| APOBEC3G | -550.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CUL5 | 5156.5 |
Somitogenesis
| 1115 | |
|---|---|
| set | Somitogenesis |
| setSize | 46 |
| pANOVA | 6.33e-12 |
| s.dist | -0.586 |
| p.adjustANOVA | 3.19e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| NOTCH1 | 769.5 |
| LFNG | 3117.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| CTNNB1 | 5054.5 |
| RBPJ | 6305.5 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
| 328 | |
|---|---|
| set | FBXL7 down-regulates AURKA during mitotic entry and in early mitosis |
| setSize | 52 |
| pANOVA | 2.95e-13 |
| s.dist | -0.585 |
| p.adjustANOVA | 2.57e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| AURKA | -1207.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| FBXL18 | -614.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
Negative regulation of NOTCH4 signaling
| 675 | |
|---|---|
| set | Negative regulation of NOTCH4 signaling |
| setSize | 53 |
| pANOVA | 3.7e-13 |
| s.dist | -0.577 |
| p.adjustANOVA | 3.03e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| YWHAZ | -3212.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| YWHAZ | -3212.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| AKT1 | -777.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| TACC3 | 1732.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| FBXW7 | 6057.5 |
Regulation of activated PAK-2p34 by proteasome mediated degradation
| 934 | |
|---|---|
| set | Regulation of activated PAK-2p34 by proteasome mediated degradation |
| setSize | 48 |
| pANOVA | 5.98e-12 |
| s.dist | -0.574 |
| p.adjustANOVA | 3.13e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PAK2 | 3931.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
Mitochondrial protein import
| 619 | |
|---|---|
| set | Mitochondrial protein import |
| setSize | 63 |
| pANOVA | 3.88e-15 |
| s.dist | -0.573 |
| p.adjustANOVA | 5.08e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TOMM5 | -3905.5 |
| COX17 | -3863.5 |
| CHCHD2 | -3794.5 |
| VDAC1 | -3773.5 |
| TIMM8B | -3716.5 |
| CHCHD10 | -3715.5 |
| NDUFB8 | -3706.5 |
| ATP5MC1 | -3701.5 |
| DNAJC19 | -3595.5 |
| GRPEL1 | -3550.5 |
| COA4 | -3538.5 |
| TIMM10B | -3489.5 |
| TIMM17A | -3465.5 |
| PAM16 | -3440.5 |
| TIMM13 | -3389.5 |
| CHCHD5 | -3291.5 |
| TOMM40 | -3249.5 |
| ATP5F1B | -3243.5 |
| TIMM44 | -3202.5 |
| CHCHD4 | -3156.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TOMM5 | -3905.5 |
| COX17 | -3863.5 |
| CHCHD2 | -3794.5 |
| VDAC1 | -3773.5 |
| TIMM8B | -3716.5 |
| CHCHD10 | -3715.5 |
| NDUFB8 | -3706.5 |
| ATP5MC1 | -3701.5 |
| DNAJC19 | -3595.5 |
| GRPEL1 | -3550.5 |
| COA4 | -3538.5 |
| TIMM10B | -3489.5 |
| TIMM17A | -3465.5 |
| PAM16 | -3440.5 |
| TIMM13 | -3389.5 |
| CHCHD5 | -3291.5 |
| TOMM40 | -3249.5 |
| ATP5F1B | -3243.5 |
| TIMM44 | -3202.5 |
| CHCHD4 | -3156.5 |
| CYC1 | -3112.5 |
| HSPD1 | -3102.5 |
| COA6 | -3056.5 |
| TIMM50 | -3055.5 |
| CHCHD7 | -3020.5 |
| CMC4 | -2823.5 |
| TIMM8A | -2555.5 |
| TIMM23 | -2509.5 |
| TIMM10 | -2455.5 |
| BCS1L | -2398.5 |
| MTX1 | -2394.5 |
| MTX2 | -2370.5 |
| GFER | -2328.5 |
| IDH3G | -2289.5 |
| ACO2 | -2240.5 |
| CMC2 | -2094.5 |
| SLC25A4 | -2031.5 |
| TIMM17B | -2022.5 |
| COQ2 | -1790.5 |
| TOMM7 | -1699.5 |
| SAMM50 | -1567.5 |
| TIMM21 | -1553.5 |
| TIMM9 | -1399.5 |
| TOMM22 | -1318.5 |
| COX19 | -1261.5 |
| TIMM22 | -1149.5 |
| FXN | -1125.5 |
| HSCB | -864.5 |
| SLC25A6 | -43.5 |
| GRPEL2 | 53.5 |
| SLC25A13 | 96.5 |
| PMPCA | 222.5 |
| CS | 590.5 |
| PITRM1 | 607.5 |
| CHCHD3 | 619.5 |
| SLC25A12 | 1940.5 |
| PMPCB | 2901.5 |
| TOMM6 | 3491.5 |
| TOMM70 | 3698.5 |
| ATP5F1A | 4334.5 |
| LDHD | 4445.5 |
| HSPA9 | 4687.5 |
| TOMM20 | 5194.5 |
Cross-presentation of soluble exogenous antigens (endosomes)
| 199 | |
|---|---|
| set | Cross-presentation of soluble exogenous antigens (endosomes) |
| setSize | 46 |
| pANOVA | 2.23e-11 |
| s.dist | -0.57 |
| p.adjustANOVA | 6.07e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| MRC2 | 2081.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| FCGR1A | 5073.5 |
| MRC1 | 7135.5 |
Ubiquitin-dependent degradation of Cyclin D
| 1254 | |
|---|---|
| set | Ubiquitin-dependent degradation of Cyclin D |
| setSize | 50 |
| pANOVA | 5.39e-12 |
| s.dist | -0.564 |
| p.adjustANOVA | 2.94e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| CDK4 | -3419.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| CDK4 | -3419.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| CCND1 | 1073.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| GSK3B | 6047.5 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
| 1253 | |
|---|---|
| set | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A |
| setSize | 49 |
| pANOVA | 9.87e-12 |
| s.dist | -0.562 |
| p.adjustANOVA | 3.57e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| CHEK2 | 389.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CHEK1 | 5191.5 |
p53-Independent DNA Damage Response
| 1293 | |
|---|---|
| set | p53-Independent DNA Damage Response |
| setSize | 49 |
| pANOVA | 9.87e-12 |
| s.dist | -0.562 |
| p.adjustANOVA | 3.57e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| CHEK2 | 389.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CHEK1 | 5191.5 |
p53-Independent G1/S DNA damage checkpoint
| 1294 | |
|---|---|
| set | p53-Independent G1/S DNA damage checkpoint |
| setSize | 49 |
| pANOVA | 9.87e-12 |
| s.dist | -0.562 |
| p.adjustANOVA | 3.57e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| CHEK2 | 389.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CHEK1 | 5191.5 |
Defective CFTR causes cystic fibrosis
| 231 | |
|---|---|
| set | Defective CFTR causes cystic fibrosis |
| setSize | 57 |
| pANOVA | 2.19e-13 |
| s.dist | -0.562 |
| p.adjustANOVA | 2.05e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| DERL1 | -3658.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| DERL1 | -3658.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| ERLIN2 | -2516.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| VCP | -2023.5 |
| RNF5 | -1877.5 |
| ERLEC1 | -1830.5 |
| RNF185 | -1702.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| ERLIN1 | 1963.5 |
| UBC | 2154.5 |
| SEL1L | 2470.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| OS9 | 6108.5 |
Gluconeogenesis
| 417 | |
|---|---|
| set | Gluconeogenesis |
| setSize | 24 |
| pANOVA | 2.01e-06 |
| s.dist | -0.56 |
| p.adjustANOVA | 2.37e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GAPDH | -3911.5 |
| ENO1 | -3786.5 |
| MDH1 | -3754.5 |
| SLC25A1 | -3709.5 |
| GOT1 | -3633.5 |
| PGK1 | -3438.5 |
| SLC25A11 | -3398.5 |
| MDH2 | -3255.5 |
| ALDOA | -3119.5 |
| TPI1 | -3052.5 |
| GOT2 | -2948.5 |
| GPI | -2433.5 |
| PGAM1 | -1983.5 |
| SLC37A2 | -1784.5 |
| G6PC3 | -1583.5 |
| FBP1 | -1098.5 |
| ENO4 | -435.5 |
| SLC37A4 | 87.5 |
| SLC25A13 | 96.5 |
| SLC37A1 | 301.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GAPDH | -3911.5 |
| ENO1 | -3786.5 |
| MDH1 | -3754.5 |
| SLC25A1 | -3709.5 |
| GOT1 | -3633.5 |
| PGK1 | -3438.5 |
| SLC25A11 | -3398.5 |
| MDH2 | -3255.5 |
| ALDOA | -3119.5 |
| TPI1 | -3052.5 |
| GOT2 | -2948.5 |
| GPI | -2433.5 |
| PGAM1 | -1983.5 |
| SLC37A2 | -1784.5 |
| G6PC3 | -1583.5 |
| FBP1 | -1098.5 |
| ENO4 | -435.5 |
| SLC37A4 | 87.5 |
| SLC25A13 | 96.5 |
| SLC37A1 | 301.5 |
| PC | 1227.5 |
| SLC25A12 | 1940.5 |
| PCK2 | 3587.5 |
| ENO2 | 4269.5 |
SCF(Skp2)-mediated degradation of p27/p21
| 987 | |
|---|---|
| set | SCF(Skp2)-mediated degradation of p27/p21 |
| setSize | 55 |
| pANOVA | 1.14e-12 |
| s.dist | -0.555 |
| p.adjustANOVA | 8.26e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| CDK4 | -3419.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| CDK4 | -3419.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| CDKN1A | -1410.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| SKP2 | -985.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| CKS1B | 162.5 |
| CCND1 | 1073.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| CDKN1B | 3475.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| CCNA1 | 5649.5 |
Hh mutants are degraded by ERAD
| 463 | |
|---|---|
| set | Hh mutants are degraded by ERAD |
| setSize | 53 |
| pANOVA | 2.91e-12 |
| s.dist | -0.554 |
| p.adjustANOVA | 1.81e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| VCP | -2023.5 |
| ERLEC1 | -1830.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| SYVN1 | 279.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| SEL1L | 2470.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| OS9 | 6108.5 |
SCF-beta-TrCP mediated degradation of Emi1
| 988 | |
|---|---|
| set | SCF-beta-TrCP mediated degradation of Emi1 |
| setSize | 51 |
| pANOVA | 7.52e-12 |
| s.dist | -0.554 |
| p.adjustANOVA | 3.39e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| FZR1 | -1003.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| BTRC | 6459.5 |
Vpu mediated degradation of CD4
| 1271 | |
|---|---|
| set | Vpu mediated degradation of CD4 |
| setSize | 51 |
| pANOVA | 8.62e-12 |
| s.dist | -0.553 |
| p.adjustANOVA | 3.57e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| vpu | -3937.5 |
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| vpu | -3937.5 |
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CD4 | 6034.5 |
| BTRC | 6459.5 |
Regulation of PTEN mRNA translation
| 918 | |
|---|---|
| set | Regulation of PTEN mRNA translation |
| setSize | 11 |
| pANOVA | 0.00162 |
| s.dist | 0.549 |
| p.adjustANOVA | 0.0103 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TNRC6B | 6727.5 |
| CNOT6L | 6570.5 |
| TNRC6A | 5747.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| PTEN | 5157.5 |
| AGO4 | 4784.5 |
| AGO2 | 4329.5 |
| MOV10 | 3442.5 |
| VAPA | 2562.5 |
| TNRC6C | 1100.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TNRC6B | 6727.5 |
| CNOT6L | 6570.5 |
| TNRC6A | 5747.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| PTEN | 5157.5 |
| AGO4 | 4784.5 |
| AGO2 | 4329.5 |
| MOV10 | 3442.5 |
| VAPA | 2562.5 |
| TNRC6C | 1100.5 |
tRNA processing in the mitochondrion
| 1306 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 18 |
| pANOVA | 6.02e-05 |
| s.dist | 0.546 |
| p.adjustANOVA | 0.000567 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-CO2 | 7159.5 |
| MT-CO1 | 7098.5 |
| MT-ND4 | 7041.5 |
| MT-ND2 | 6979.5 |
| MT-CYB | 6967.5 |
| MT-ATP6 | 6895.5 |
| MT-ATP8 | 6865.5 |
| MT-ND5 | 6812.5 |
| MT-CO3 | 6561.5 |
| MT-ND1 | 6243.5 |
| MT-ND4L | 5603.5 |
| MT-ND3 | 4440.5 |
| PRORP | 4037.5 |
| MT-ND6 | 3175.5 |
| TRMT10C | 1524.5 |
| TRNT1 | 763.5 |
| ELAC2 | -1024.5 |
| HSD17B10 | -3369.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-CO2 | 7159.5 |
| MT-CO1 | 7098.5 |
| MT-ND4 | 7041.5 |
| MT-ND2 | 6979.5 |
| MT-CYB | 6967.5 |
| MT-ATP6 | 6895.5 |
| MT-ATP8 | 6865.5 |
| MT-ND5 | 6812.5 |
| MT-CO3 | 6561.5 |
| MT-ND1 | 6243.5 |
| MT-ND4L | 5603.5 |
| MT-ND3 | 4440.5 |
| PRORP | 4037.5 |
| MT-ND6 | 3175.5 |
| TRMT10C | 1524.5 |
| TRNT1 | 763.5 |
| ELAC2 | -1024.5 |
| HSD17B10 | -3369.5 |
Asymmetric localization of PCP proteins
| 78 | |
|---|---|
| set | Asymmetric localization of PCP proteins |
| setSize | 51 |
| pANOVA | 1.65e-11 |
| s.dist | -0.545 |
| p.adjustANOVA | 4.9e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| SCRIB | -1715.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| DVL2 | 723.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| SMURF1 | 2480.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| SMURF2 | 5956.5 |
Autodegradation of the E3 ubiquitin ligase COP1
| 82 | |
|---|---|
| set | Autodegradation of the E3 ubiquitin ligase COP1 |
| setSize | 49 |
| pANOVA | 4.53e-11 |
| s.dist | -0.544 |
| p.adjustANOVA | 1.06e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| TP53 | 3677.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| ATM | 6887.5 |
Cholesterol biosynthesis
| 161 | |
|---|---|
| set | Cholesterol biosynthesis |
| setSize | 25 |
| pANOVA | 2.96e-06 |
| s.dist | -0.54 |
| p.adjustANOVA | 3.43e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DHCR24 | -3750.5 |
| IDI1 | -3732.5 |
| FDPS | -3484.5 |
| MSMO1 | -3325.5 |
| PMVK | -3310.5 |
| CYP51A1 | -3224.5 |
| SC5D | -3076.5 |
| MVK | -3049.5 |
| SQLE | -3044.5 |
| EBP | -2855.5 |
| FDFT1 | -2735.5 |
| DHCR7 | -2655.5 |
| HMGCR | -2359.5 |
| HMGCS1 | -2257.5 |
| GGPS1 | -2233.5 |
| HSD17B7 | -2114.5 |
| MVD | -1618.5 |
| ACAT2 | -336.5 |
| SREBF2 | 350.5 |
| NSDHL | 383.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DHCR24 | -3750.5 |
| IDI1 | -3732.5 |
| FDPS | -3484.5 |
| MSMO1 | -3325.5 |
| PMVK | -3310.5 |
| CYP51A1 | -3224.5 |
| SC5D | -3076.5 |
| MVK | -3049.5 |
| SQLE | -3044.5 |
| EBP | -2855.5 |
| FDFT1 | -2735.5 |
| DHCR7 | -2655.5 |
| HMGCR | -2359.5 |
| HMGCS1 | -2257.5 |
| GGPS1 | -2233.5 |
| HSD17B7 | -2114.5 |
| MVD | -1618.5 |
| ACAT2 | -336.5 |
| SREBF2 | 350.5 |
| NSDHL | 383.5 |
| LBR | 857.5 |
| ARV1 | 2202.5 |
| SREBF1 | 2916.5 |
| TM7SF2 | 3678.5 |
| LSS | 4306.5 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation
| 182 | |
|---|---|
| set | Competing endogenous RNAs (ceRNAs) regulate PTEN translation |
| setSize | 10 |
| pANOVA | 0.00311 |
| s.dist | 0.54 |
| p.adjustANOVA | 0.0173 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TNRC6B | 6727.5 |
| CNOT6L | 6570.5 |
| TNRC6A | 5747.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| AGO4 | 4784.5 |
| AGO2 | 4329.5 |
| MOV10 | 3442.5 |
| VAPA | 2562.5 |
| TNRC6C | 1100.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TNRC6B | 6727.5 |
| CNOT6L | 6570.5 |
| TNRC6A | 5747.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| AGO4 | 4784.5 |
| AGO2 | 4329.5 |
| MOV10 | 3442.5 |
| VAPA | 2562.5 |
| TNRC6C | 1100.5 |
Degradation of DVL
| 243 | |
|---|---|
| set | Degradation of DVL |
| setSize | 53 |
| pANOVA | 1.16e-11 |
| s.dist | -0.539 |
| p.adjustANOVA | 3.8e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| DVL1 | -2378.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| DVL2 | 723.5 |
| DVL3 | 1544.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| KLHL12 | 2725.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CUL3 | 6882.5 |
NRAGE signals death through JNK
| 661 | |
|---|---|
| set | NRAGE signals death through JNK |
| setSize | 36 |
| pANOVA | 2.26e-08 |
| s.dist | 0.539 |
| p.adjustANOVA | 3.43e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KALRN | 7143.5 |
| SOS1 | 7033.5 |
| ARHGEF3 | 7024.5 |
| FGD4 | 6980.5 |
| GNA13 | 6951.5 |
| AKAP13 | 6730.5 |
| ITSN1 | 6685.5 |
| SOS2 | 6643.5 |
| ARHGEF6 | 6599.5 |
| ARHGEF2 | 6403.5 |
| TIAM1 | 6388.5 |
| TRIO | 6382.5 |
| BCL2L11 | 6312.5 |
| ABR | 6287.5 |
| MAGED1 | 6279.5 |
| ARHGEF1 | 6042.5 |
| MAPK8 | 6031.5 |
| ARHGEF7 | 5817.5 |
| VAV3 | 5701.5 |
| VAV1 | 5489.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KALRN | 7143.5 |
| SOS1 | 7033.5 |
| ARHGEF3 | 7024.5 |
| FGD4 | 6980.5 |
| GNA13 | 6951.5 |
| AKAP13 | 6730.5 |
| ITSN1 | 6685.5 |
| SOS2 | 6643.5 |
| ARHGEF6 | 6599.5 |
| ARHGEF2 | 6403.5 |
| TIAM1 | 6388.5 |
| TRIO | 6382.5 |
| BCL2L11 | 6312.5 |
| ABR | 6287.5 |
| MAGED1 | 6279.5 |
| ARHGEF1 | 6042.5 |
| MAPK8 | 6031.5 |
| ARHGEF7 | 5817.5 |
| VAV3 | 5701.5 |
| VAV1 | 5489.5 |
| ARHGEF18 | 5236.5 |
| ARHGEF11 | 5163.5 |
| VAV2 | 4935.5 |
| PREX1 | 4874.5 |
| ECT2 | 4753.5 |
| ARHGEF40 | 4723.5 |
| ARHGEF12 | 4295.5 |
| FGD3 | 3264.5 |
| TIAM2 | 2981.5 |
| ARHGEF9 | 2116.5 |
| ARHGEF10L | 1976.5 |
| AATF | 1763.5 |
| ARHGEF35 | -971.5 |
| RAC1 | -2107.5 |
| FGD2 | -2620.5 |
| BAD | -3474.5 |
Regulation of Apoptosis
| 901 | |
|---|---|
| set | Regulation of Apoptosis |
| setSize | 51 |
| pANOVA | 3.36e-11 |
| s.dist | -0.537 |
| p.adjustANOVA | 8.44e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| OMA1 | -3071.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| OMA1 | -3071.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PAK2 | 3931.5 |
| OPA1 | 4419.5 |
| ARHGAP10 | 4539.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
mRNA decay by 3’ to 5’ exoribonuclease
| 1286 | |
|---|---|
| set | mRNA decay by 3’ to 5’ exoribonuclease |
| setSize | 13 |
| pANOVA | 0.000927 |
| s.dist | -0.531 |
| p.adjustANOVA | 0.00635 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NT5C3B | -3719.5 |
| EXOSC8 | -3268.5 |
| EXOSC5 | -2740.5 |
| EXOSC7 | -2592.5 |
| EXOSC3 | -2584.5 |
| DCPS | -2444.5 |
| EXOSC9 | -2078.5 |
| EXOSC4 | -1914.5 |
| EXOSC2 | -1568.5 |
| EXOSC1 | -1018.5 |
| EXOSC6 | -210.5 |
| DIS3 | 2319.5 |
| HBS1L | 4538.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NT5C3B | -3719.5 |
| EXOSC8 | -3268.5 |
| EXOSC5 | -2740.5 |
| EXOSC7 | -2592.5 |
| EXOSC3 | -2584.5 |
| DCPS | -2444.5 |
| EXOSC9 | -2078.5 |
| EXOSC4 | -1914.5 |
| EXOSC2 | -1568.5 |
| EXOSC1 | -1018.5 |
| EXOSC6 | -210.5 |
| DIS3 | 2319.5 |
| HBS1L | 4538.5 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
| 398 | |
|---|---|
| set | GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 |
| setSize | 52 |
| pANOVA | 3.7e-11 |
| s.dist | -0.53 |
| p.adjustANOVA | 9.12e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| GSK3B | 6047.5 |
| NFE2L2 | 6252.5 |
| BTRC | 6459.5 |
HDMs demethylate histones
| 440 | |
|---|---|
| set | HDMs demethylate histones |
| setSize | 21 |
| pANOVA | 2.6e-05 |
| s.dist | 0.53 |
| p.adjustANOVA | 0.000261 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KDM5B | 7148.5 |
| ARID5B | 6953.5 |
| KDM6A | 6834.5 |
| KDM5A | 6802.5 |
| KDM2A | 6751.5 |
| KDM7A | 5849.5 |
| KDM4B | 5832.5 |
| KDM6B | 5433.5 |
| KDM1B | 5389.5 |
| KDM3B | 5322.5 |
| KDM3A | 4949.5 |
| KDM1A | 4794.5 |
| KDM4C | 4595.5 |
| PHF2 | 3975.5 |
| KDM4A | 3851.5 |
| PHF8 | 3460.5 |
| KDM5C | 3099.5 |
| KDM2B | 2392.5 |
| UTY | 2303.5 |
| KDM5D | 1360.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KDM5B | 7148.5 |
| ARID5B | 6953.5 |
| KDM6A | 6834.5 |
| KDM5A | 6802.5 |
| KDM2A | 6751.5 |
| KDM7A | 5849.5 |
| KDM4B | 5832.5 |
| KDM6B | 5433.5 |
| KDM1B | 5389.5 |
| KDM3B | 5322.5 |
| KDM3A | 4949.5 |
| KDM1A | 4794.5 |
| KDM4C | 4595.5 |
| PHF2 | 3975.5 |
| KDM4A | 3851.5 |
| PHF8 | 3460.5 |
| KDM5C | 3099.5 |
| KDM2B | 2392.5 |
| UTY | 2303.5 |
| KDM5D | 1360.5 |
| JMJD6 | -1242.5 |
Hh mutants abrogate ligand secretion
| 462 | |
|---|---|
| set | Hh mutants abrogate ligand secretion |
| setSize | 54 |
| pANOVA | 1.72e-11 |
| s.dist | -0.529 |
| p.adjustANOVA | 4.93e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| DERL2 | -3065.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| VCP | -2023.5 |
| ERLEC1 | -1830.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| SYVN1 | 279.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| SEL1L | 2470.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| HHAT | 6059.5 |
| OS9 | 6108.5 |
Autodegradation of Cdh1 by Cdh1:APC/C
| 81 | |
|---|---|
| set | Autodegradation of Cdh1 by Cdh1:APC/C |
| setSize | 62 |
| pANOVA | 6.39e-13 |
| s.dist | -0.528 |
| p.adjustANOVA | 4.92e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| ANAPC11 | -3877.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| UBE2S | -3345.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| ANAPC11 | -3877.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| UBE2S | -3345.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| ANAPC15 | -2963.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| ANAPC16 | -2755.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| CDC23 | -1582.5 |
| PSMD12 | -1549.5 |
| CDC26 | -1522.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| FZR1 | -1003.5 |
| ANAPC10 | -995.5 |
| UBA52 | -764.5 |
| CDC16 | -723.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| ANAPC5 | -164.5 |
| PSME2 | 135.5 |
| ANAPC1 | 1333.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| ANAPC4 | 2817.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| CDC27 | 3571.5 |
| UBE2E1 | 3773.5 |
| ANAPC7 | 3866.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| UBE2D1 | 6500.5 |
Complex I biogenesis
| 184 | |
|---|---|
| set | Complex I biogenesis |
| setSize | 57 |
| pANOVA | 7.06e-12 |
| s.dist | -0.525 |
| p.adjustANOVA | 3.38e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NDUFS6 | -3909.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| NDUFA13 | -3792.5 |
| NDUFAF3 | -3733.5 |
| NDUFB8 | -3706.5 |
| NDUFA6 | -3704.5 |
| NDUFS7 | -3699.5 |
| NDUFS8 | -3691.5 |
| NDUFB1 | -3647.5 |
| NDUFA8 | -3626.5 |
| NDUFA12 | -3612.5 |
| NDUFB10 | -3601.5 |
| NDUFB3 | -3445.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NDUFS6 | -3909.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| NDUFA13 | -3792.5 |
| NDUFAF3 | -3733.5 |
| NDUFB8 | -3706.5 |
| NDUFA6 | -3704.5 |
| NDUFS7 | -3699.5 |
| NDUFS8 | -3691.5 |
| NDUFB1 | -3647.5 |
| NDUFA8 | -3626.5 |
| NDUFA12 | -3612.5 |
| NDUFB10 | -3601.5 |
| NDUFB3 | -3445.5 |
| NDUFV3 | -3417.5 |
| NDUFA2 | -3390.5 |
| NDUFA1 | -3354.5 |
| NDUFB4 | -3351.5 |
| NDUFAF2 | -3349.5 |
| NDUFA5 | -3327.5 |
| NDUFC2 | -3205.5 |
| NDUFAF4 | -3189.5 |
| NDUFB6 | -2991.5 |
| NDUFV1 | -2865.5 |
| NDUFA9 | -2827.5 |
| NDUFAF1 | -2761.5 |
| NDUFS3 | -2750.5 |
| NDUFB11 | -2557.5 |
| TMEM126B | -1543.5 |
| NDUFAF5 | -1202.5 |
| NDUFA3 | -1141.5 |
| NDUFS2 | -917.5 |
| TIMMDC1 | -473.5 |
| COA1 | -353.5 |
| ECSIT | -303.5 |
| NDUFA10 | -287.5 |
| NDUFS4 | -75.5 |
| TMEM186 | 13.5 |
| NUBPL | 29.5 |
| NDUFAF7 | 1323.5 |
| ACAD9 | 1691.5 |
| NDUFB5 | 2345.5 |
| NDUFB9 | 3119.5 |
| MT-ND6 | 3175.5 |
| NDUFS1 | 3389.5 |
| MT-ND3 | 4440.5 |
| NDUFAF6 | 4660.5 |
| MT-ND1 | 6243.5 |
| MT-ND5 | 6812.5 |
| MT-ND2 | 6979.5 |
| MT-ND4 | 7041.5 |
Regulation of RUNX3 expression and activity
| 923 | |
|---|---|
| set | Regulation of RUNX3 expression and activity |
| setSize | 55 |
| pANOVA | 3.13e-11 |
| s.dist | -0.518 |
| p.adjustANOVA | 8.03e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| TGFB1 | -3441.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| TGFB1 | -3441.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| UBA52 | -764.5 |
| MDM2 | -569.5 |
| SRC | -369.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| RUNX3 | 668.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| SMURF1 | 2480.5 |
| CDKN2A | 2578.5 |
| CBFB | 2794.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSMB9 | 5000.5 |
| EP300 | 5046.5 |
| SMURF2 | 5956.5 |
APC/C:Cdc20 mediated degradation of Securin
| 14 | |
|---|---|
| set | APC/C:Cdc20 mediated degradation of Securin |
| setSize | 63 |
| pANOVA | 1.35e-12 |
| s.dist | -0.517 |
| p.adjustANOVA | 9.32e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| ANAPC11 | -3877.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| UBE2S | -3345.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PTTG1 | -3113.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| ANAPC11 | -3877.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| UBE2S | -3345.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PTTG1 | -3113.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| ANAPC15 | -2963.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| ANAPC16 | -2755.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| CDC23 | -1582.5 |
| PSMD12 | -1549.5 |
| CDC26 | -1522.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| ANAPC10 | -995.5 |
| UBA52 | -764.5 |
| CDC16 | -723.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| ANAPC5 | -164.5 |
| PSME2 | 135.5 |
| ANAPC1 | 1333.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| ANAPC4 | 2817.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| CDC27 | 3571.5 |
| UBE2E1 | 3773.5 |
| ANAPC7 | 3866.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| UBE2D1 | 6500.5 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
| 961 | |
|---|---|
| set | Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. |
| setSize | 123 |
| pANOVA | 6.97e-23 |
| s.dist | -0.514 |
| p.adjustANOVA | 1.52e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| COX8A | -3917.5 |
| NDUFS6 | -3909.5 |
| COX6C | -3891.5 |
| ATP5PF | -3888.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| CYCS | -3864.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| UQCRQ | -3835.5 |
| ATP5MF | -3834.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| COX7B | -3799.5 |
| COX6A1 | -3797.5 |
| NDUFA13 | -3792.5 |
| COX7A2L | -3771.5 |
| NDUFAF3 | -3733.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| COX8A | -3917.5 |
| NDUFS6 | -3909.5 |
| COX6C | -3891.5 |
| ATP5PF | -3888.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| CYCS | -3864.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| UQCRQ | -3835.5 |
| ATP5MF | -3834.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| COX7B | -3799.5 |
| COX6A1 | -3797.5 |
| NDUFA13 | -3792.5 |
| COX7A2L | -3771.5 |
| NDUFAF3 | -3733.5 |
| NDUFA4 | -3723.5 |
| NDUFB8 | -3706.5 |
| NDUFA6 | -3704.5 |
| ATP5MC1 | -3701.5 |
| NDUFS7 | -3699.5 |
| NDUFS8 | -3691.5 |
| ATP5PD | -3680.5 |
| ATP5F1E | -3650.5 |
| NDUFB1 | -3647.5 |
| UQCR11 | -3630.5 |
| NDUFA8 | -3626.5 |
| UQCRC1 | -3624.5 |
| NDUFA12 | -3612.5 |
| NDUFB10 | -3601.5 |
| ATP5MC3 | -3600.5 |
| ATP5ME | -3575.5 |
| COX5A | -3493.5 |
| ETFB | -3485.5 |
| COX14 | -3476.5 |
| NDUFB3 | -3445.5 |
| NDUFV3 | -3417.5 |
| COX16 | -3409.5 |
| COX7C | -3406.5 |
| NDUFA2 | -3390.5 |
| COX20 | -3357.5 |
| NDUFA1 | -3354.5 |
| NDUFB4 | -3351.5 |
| NDUFAF2 | -3349.5 |
| SURF1 | -3330.5 |
| NDUFA5 | -3327.5 |
| COX6B1 | -3321.5 |
| UQCRH | -3288.5 |
| ATP5F1B | -3243.5 |
| UQCR10 | -3207.5 |
| NDUFC2 | -3205.5 |
| NDUFAF4 | -3189.5 |
| ATP5MG | -3178.5 |
| ATP5PO | -3128.5 |
| CYC1 | -3112.5 |
| COX11 | -3089.5 |
| SDHB | -3057.5 |
| NDUFB6 | -2991.5 |
| ATP5PB | -2981.5 |
| UQCRFS1 | -2869.5 |
| NDUFV1 | -2865.5 |
| NDUFA9 | -2827.5 |
| NDUFAF1 | -2761.5 |
| NDUFS3 | -2750.5 |
| DMAC2L | -2738.5 |
| ATP5F1C | -2636.5 |
| UCP2 | -2560.5 |
| NDUFB11 | -2557.5 |
| SLC25A14 | -2391.5 |
| COQ10B | -1926.5 |
| ETFA | -1905.5 |
| COX4I1 | -1867.5 |
| COQ10A | -1623.5 |
| TMEM126B | -1543.5 |
| SCO1 | -1537.5 |
| SCO2 | -1470.5 |
| SDHD | -1382.5 |
| COX19 | -1261.5 |
| ETFDH | -1211.5 |
| NDUFAF5 | -1202.5 |
| TACO1 | -1160.5 |
| NDUFA3 | -1141.5 |
| NDUFS2 | -917.5 |
| TIMMDC1 | -473.5 |
| COA1 | -353.5 |
| ECSIT | -303.5 |
| NDUFA10 | -287.5 |
| SDHC | -191.5 |
| NDUFS4 | -75.5 |
| TMEM186 | 13.5 |
| NUBPL | 29.5 |
| ATP5F1D | 376.5 |
| TRAP1 | 610.5 |
| NDUFAF7 | 1323.5 |
| COX18 | 1514.5 |
| LRPPRC | 1670.5 |
| ACAD9 | 1691.5 |
| NDUFB5 | 2345.5 |
| SDHA | 2378.5 |
| NDUFB9 | 3119.5 |
| MT-ND6 | 3175.5 |
| NDUFS1 | 3389.5 |
| ATP5F1A | 4334.5 |
| UQCRC2 | 4383.5 |
| MT-ND3 | 4440.5 |
| COX5B | 4593.5 |
| NDUFAF6 | 4660.5 |
| UQCRB | 4832.5 |
| ATP5MC2 | 6219.5 |
| MT-ND1 | 6243.5 |
| MT-CO3 | 6561.5 |
| MT-ND5 | 6812.5 |
| MT-ATP8 | 6865.5 |
| MT-ATP6 | 6895.5 |
| MT-CYB | 6967.5 |
| MT-ND2 | 6979.5 |
| MT-ND4 | 7041.5 |
| MT-CO1 | 7098.5 |
| MT-CO2 | 7159.5 |
Respiratory electron transport
| 960 | |
|---|---|
| set | Respiratory electron transport |
| setSize | 103 |
| pANOVA | 2.16e-19 |
| s.dist | -0.514 |
| p.adjustANOVA | 4.03e-17 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| COX8A | -3917.5 |
| NDUFS6 | -3909.5 |
| COX6C | -3891.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| CYCS | -3864.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| UQCRQ | -3835.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| COX7B | -3799.5 |
| COX6A1 | -3797.5 |
| NDUFA13 | -3792.5 |
| COX7A2L | -3771.5 |
| NDUFAF3 | -3733.5 |
| NDUFA4 | -3723.5 |
| NDUFB8 | -3706.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| COX8A | -3917.5 |
| NDUFS6 | -3909.5 |
| COX6C | -3891.5 |
| NDUFA11 | -3887.5 |
| NDUFB2 | -3884.5 |
| NDUFB7 | -3883.5 |
| CYCS | -3864.5 |
| NDUFAB1 | -3858.5 |
| NDUFA7 | -3852.5 |
| NDUFC1 | -3849.5 |
| UQCRQ | -3835.5 |
| NDUFS5 | -3831.5 |
| NDUFV2 | -3816.5 |
| COX7B | -3799.5 |
| COX6A1 | -3797.5 |
| NDUFA13 | -3792.5 |
| COX7A2L | -3771.5 |
| NDUFAF3 | -3733.5 |
| NDUFA4 | -3723.5 |
| NDUFB8 | -3706.5 |
| NDUFA6 | -3704.5 |
| NDUFS7 | -3699.5 |
| NDUFS8 | -3691.5 |
| NDUFB1 | -3647.5 |
| UQCR11 | -3630.5 |
| NDUFA8 | -3626.5 |
| UQCRC1 | -3624.5 |
| NDUFA12 | -3612.5 |
| NDUFB10 | -3601.5 |
| COX5A | -3493.5 |
| ETFB | -3485.5 |
| COX14 | -3476.5 |
| NDUFB3 | -3445.5 |
| NDUFV3 | -3417.5 |
| COX16 | -3409.5 |
| COX7C | -3406.5 |
| NDUFA2 | -3390.5 |
| COX20 | -3357.5 |
| NDUFA1 | -3354.5 |
| NDUFB4 | -3351.5 |
| NDUFAF2 | -3349.5 |
| SURF1 | -3330.5 |
| NDUFA5 | -3327.5 |
| COX6B1 | -3321.5 |
| UQCRH | -3288.5 |
| UQCR10 | -3207.5 |
| NDUFC2 | -3205.5 |
| NDUFAF4 | -3189.5 |
| CYC1 | -3112.5 |
| COX11 | -3089.5 |
| SDHB | -3057.5 |
| NDUFB6 | -2991.5 |
| UQCRFS1 | -2869.5 |
| NDUFV1 | -2865.5 |
| NDUFA9 | -2827.5 |
| NDUFAF1 | -2761.5 |
| NDUFS3 | -2750.5 |
| NDUFB11 | -2557.5 |
| COQ10B | -1926.5 |
| ETFA | -1905.5 |
| COX4I1 | -1867.5 |
| COQ10A | -1623.5 |
| TMEM126B | -1543.5 |
| SCO1 | -1537.5 |
| SCO2 | -1470.5 |
| SDHD | -1382.5 |
| COX19 | -1261.5 |
| ETFDH | -1211.5 |
| NDUFAF5 | -1202.5 |
| TACO1 | -1160.5 |
| NDUFA3 | -1141.5 |
| NDUFS2 | -917.5 |
| TIMMDC1 | -473.5 |
| COA1 | -353.5 |
| ECSIT | -303.5 |
| NDUFA10 | -287.5 |
| SDHC | -191.5 |
| NDUFS4 | -75.5 |
| TMEM186 | 13.5 |
| NUBPL | 29.5 |
| TRAP1 | 610.5 |
| NDUFAF7 | 1323.5 |
| COX18 | 1514.5 |
| LRPPRC | 1670.5 |
| ACAD9 | 1691.5 |
| NDUFB5 | 2345.5 |
| SDHA | 2378.5 |
| NDUFB9 | 3119.5 |
| MT-ND6 | 3175.5 |
| NDUFS1 | 3389.5 |
| UQCRC2 | 4383.5 |
| MT-ND3 | 4440.5 |
| COX5B | 4593.5 |
| NDUFAF6 | 4660.5 |
| UQCRB | 4832.5 |
| MT-ND1 | 6243.5 |
| MT-CO3 | 6561.5 |
| MT-ND5 | 6812.5 |
| MT-CYB | 6967.5 |
| MT-ND2 | 6979.5 |
| MT-ND4 | 7041.5 |
| MT-CO1 | 7098.5 |
| MT-CO2 | 7159.5 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
| 660 | |
|---|---|
| set | NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux |
| setSize | 34 |
| pANOVA | 2.52e-07 |
| s.dist | 0.511 |
| p.adjustANOVA | 3.43e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ABCA1 | 7001.5 |
| APOD | 6866.5 |
| NCOR1 | 6830.5 |
| NR1H3 | 6794.5 |
| TNRC6B | 6727.5 |
| NCOA1 | 6628.5 |
| APOE | 6531.5 |
| TBL1XR1 | 6405.5 |
| TBL1X | 6266.5 |
| EEPD1 | 5819.5 |
| TNRC6A | 5747.5 |
| NCOR2 | 5655.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| KDM1B | 5389.5 |
| ARL4C | 5317.5 |
| EP300 | 5046.5 |
| KDM3A | 4949.5 |
| PLTP | 4899.5 |
| KDM1A | 4794.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ABCA1 | 7001.5 |
| APOD | 6866.5 |
| NCOR1 | 6830.5 |
| NR1H3 | 6794.5 |
| TNRC6B | 6727.5 |
| NCOA1 | 6628.5 |
| APOE | 6531.5 |
| TBL1XR1 | 6405.5 |
| TBL1X | 6266.5 |
| EEPD1 | 5819.5 |
| TNRC6A | 5747.5 |
| NCOR2 | 5655.5 |
| AGO1 | 5479.5 |
| AGO3 | 5473.5 |
| KDM1B | 5389.5 |
| ARL4C | 5317.5 |
| EP300 | 5046.5 |
| KDM3A | 4949.5 |
| PLTP | 4899.5 |
| KDM1A | 4794.5 |
| AGO4 | 4784.5 |
| ABCG1 | 4607.5 |
| APOC4 | 4468.5 |
| AGO2 | 4329.5 |
| APOC1 | 4147.5 |
| APOC2 | 4007.5 |
| KDM4A | 3851.5 |
| MOV10 | 3442.5 |
| RXRA | 2203.5 |
| RXRB | 1622.5 |
| TNRC6C | 1100.5 |
| HDAC3 | -655.5 |
| NR1H2 | -1803.5 |
| GPS2 | -3273.5 |
AUF1 (hnRNP D0) binds and destabilizes mRNA
| 22 | |
|---|---|
| set | AUF1 (hnRNP D0) binds and destabilizes mRNA |
| setSize | 53 |
| pANOVA | 1.74e-10 |
| s.dist | -0.507 |
| p.adjustANOVA | 3.45e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| HSPA8 | -996.5 |
| UBA52 | -764.5 |
| HNRNPD | -361.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| PSME2 | 135.5 |
| EIF4G1 | 1349.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| HSPB1 | 4235.5 |
| HSPA1A | 4558.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| PABPC1 | 7095.5 |
2-LTR circle formation
| 1 | |
|---|---|
| set | 2-LTR circle formation |
| setSize | 12 |
| pANOVA | 0.00258 |
| s.dist | -0.503 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| HMGA1 | -3736.5 |
| rev | -3664.5 |
| BANF1 | -3254.5 |
| XRCC6 | -922.5 |
| LIG4 | 303.5 |
| PSIP1 | 2964.5 |
| XRCC4 | 3743.5 |
| XRCC5 | 6229.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| gag | -3944.5 |
| vif | -3939.5 |
| vpu | -3937.5 |
| vpr | -3929.5 |
| HMGA1 | -3736.5 |
| rev | -3664.5 |
| BANF1 | -3254.5 |
| XRCC6 | -922.5 |
| LIG4 | 303.5 |
| PSIP1 | 2964.5 |
| XRCC4 | 3743.5 |
| XRCC5 | 6229.5 |
Orc1 removal from chromatin
| 716 | |
|---|---|
| set | Orc1 removal from chromatin |
| setSize | 60 |
| pANOVA | 1.92e-11 |
| s.dist | -0.501 |
| p.adjustANOVA | 5.34e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PSMD8 | -3890.5 |
| PSMA7 | -3842.5 |
| PSMA4 | -3749.5 |
| PSMB7 | -3717.5 |
| SEM1 | -3660.5 |
| PSMB1 | -3644.5 |
| PSMB6 | -3635.5 |
| PSMB3 | -3625.5 |
| PSMC3 | -3475.5 |
| PSMA3 | -3469.5 |
| PSMD7 | -3431.5 |
| PSMD14 | -3430.5 |
| PSMB2 | -3391.5 |
| PSMA2 | -3339.5 |
| PSMA6 | -3328.5 |
| SKP1 | -3252.5 |
| PSMC4 | -3247.5 |
| PSMD10 | -3209.5 |
| PSMC5 | -3067.5 |
| PSMC1 | -2972.5 |
| RBX1 | -2970.5 |
| PSMD3 | -2906.5 |
| PSMA5 | -2836.5 |
| PSMD9 | -2737.5 |
| PSMD13 | -2650.5 |
| PSMD2 | -2632.5 |
| PSMD1 | -2442.5 |
| PSMC2 | -2397.5 |
| PSMD11 | -2353.5 |
| PSMD6 | -2323.5 |
| PSMA1 | -2263.5 |
| PSMD4 | -2236.5 |
| PSMC6 | -2185.5 |
| PSMD12 | -1549.5 |
| PSME3 | -1507.5 |
| PSMF1 | -1307.5 |
| PSMB10 | -1295.5 |
| PSME1 | -1058.5 |
| SKP2 | -985.5 |
| UBA52 | -764.5 |
| ORC4 | -653.5 |
| PSMB5 | -307.5 |
| PSMB8 | -273.5 |
| ORC3 | 85.5 |
| PSME2 | 135.5 |
| ORC6 | 853.5 |
| MCM5 | 928.5 |
| MCM3 | 979.5 |
| ORC5 | 1173.5 |
| UBB | 1916.5 |
| UBC | 2154.5 |
| MCM6 | 2502.5 |
| ORC2 | 2633.5 |
| CUL1 | 2654.5 |
| RPS27A | 2976.5 |
| PSMB4 | 3449.5 |
| PSMD5 | 4775.5 |
| PSME4 | 4894.5 |
| PSMB9 | 5000.5 |
| CCNA1 | 5649.5 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats graphics grDevices utils datasets methods base
##
## other attached packages:
## [1] stringr_1.5.0 harmony_0.1.1 Rcpp_1.0.11
## [4] tidyr_1.3.0 SeuratWrappers_0.3.1 SeuratObject_4.1.3
## [7] Seurat_4.3.0.1 pkgload_1.3.2.1 GGally_2.1.2
## [10] ggplot2_3.4.3 reshape2_1.4.4 beeswarm_0.4.0
## [13] gtools_3.9.4 tibble_3.2.1 dplyr_1.1.3
## [16] echarts4r_0.4.5 kableExtra_1.3.4 gplots_3.1.3
## [19] mitch_1.12.0
##
## loaded via a namespace (and not attached):
## [1] RColorBrewer_1.1-3 rstudioapi_0.15.0 jsonlite_1.8.7
## [4] magrittr_2.0.3 spatstat.utils_3.0-3 farver_2.1.1
## [7] rmarkdown_2.25 vctrs_0.6.3 ROCR_1.0-11
## [10] spatstat.explore_3.2-3 webshot_0.5.5 htmltools_0.5.6
## [13] sass_0.4.7 sctransform_0.3.5 parallelly_1.36.0
## [16] KernSmooth_2.23-22 bslib_0.5.1 htmlwidgets_1.6.2
## [19] ica_1.0-3 plyr_1.8.8 plotly_4.10.2
## [22] zoo_1.8-12 cachem_1.0.8 igraph_1.5.1
## [25] mime_0.12 lifecycle_1.0.3 pkgconfig_2.0.3
## [28] rsvd_1.0.5 Matrix_1.6-1.1 R6_2.5.1
## [31] fastmap_1.1.1 fitdistrplus_1.1-11 future_1.33.0
## [34] shiny_1.7.5 digest_0.6.33 colorspace_2.1-0
## [37] reshape_0.8.9 patchwork_1.1.3 tensor_1.5
## [40] irlba_2.3.5.1 labeling_0.4.3 progressr_0.14.0
## [43] fansi_1.0.4 spatstat.sparse_3.0-2 httr_1.4.7
## [46] polyclip_1.10-4 abind_1.4-5 compiler_4.3.1
## [49] remotes_2.4.2.1 withr_2.5.0 highr_0.10
## [52] R.utils_2.12.2 MASS_7.3-60 caTools_1.18.2
## [55] tools_4.3.1 lmtest_0.9-40 httpuv_1.6.11
## [58] future.apply_1.11.0 goftest_1.2-3 R.oo_1.25.0
## [61] glue_1.6.2 nlme_3.1-163 promises_1.2.1
## [64] grid_4.3.1 Rtsne_0.16 cluster_2.1.4
## [67] generics_0.1.3 gtable_0.3.4 spatstat.data_3.0-1
## [70] R.methodsS3_1.8.2 data.table_1.14.8 sp_2.0-0
## [73] xml2_1.3.5 utf8_1.2.3 spatstat.geom_3.2-5
## [76] RcppAnnoy_0.0.21 ggrepel_0.9.3 RANN_2.6.1
## [79] pillar_1.9.0 later_1.3.1 splines_4.3.1
## [82] lattice_0.21-8 survival_3.5-7 deldir_1.0-9
## [85] tidyselect_1.2.0 miniUI_0.1.1.1 pbapply_1.7-2
## [88] knitr_1.44 gridExtra_2.3 svglite_2.1.1
## [91] scattermore_1.2 xfun_0.40 matrixStats_1.0.0
## [94] stringi_1.7.12 lazyeval_0.2.2 yaml_2.3.7
## [97] evaluate_0.21 codetools_0.2-19 BiocManager_1.30.22
## [100] cli_3.6.1 uwot_0.1.16 xtable_1.8-4
## [103] reticulate_1.32.0 systemfonts_1.0.4 munsell_0.5.0
## [106] jquerylib_0.1.4 globals_0.16.2 spatstat.random_3.1-6
## [109] png_0.1-8 parallel_4.3.1 ellipsis_0.3.2
## [112] bitops_1.0-7 listenv_0.9.0 viridisLite_0.4.2
## [115] scales_1.2.1 ggridges_0.5.4 leiden_0.4.3
## [118] purrr_1.0.2 rlang_1.1.1 cowplot_1.1.1
## [121] rvest_1.0.3END of report